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Abstract 
     Organophosphate (OP) poisoning is a health issue worldwide with over 200,000 
deaths per year.  Although not a problem in most developed countries, in some third 
world countries, one third of a hospital’s population could be patients with OP 
exposure.  Even with the most aggressive therapy, 10-40% of patients admitted to an 
intensive care unit will die.  Research into the best practice for treating OP poisoning is 
lacking, due somewhat to a lack of detailed understanding of the physiology of OP 
poisoning.  Our research uses animal models of acute OP poisoning to explore the 
mechanism of OP-induced respiratory failure. 
 
      Our research shows that animals poisoned with dichlorvos demonstrated a 
uniformly fatal central apnea that, if prevented, was followed immediately by a variable 
pulmonary dysfunction.  Potential mechanisms for dichlorvos-induced central apnea 
can be divided into direct effects on the central respiratory oscillator (CRO) and 
feedback inhibition of the CRO.  Two afferent pathways that can induce apnea include 
vagal feedback pathways and feed-forward pathways from the cerebral hemispheres.  
In our studies we found that vagal feedback and feed forward inhibition from the 
cerebral hemispheres were not required for OP-induced central apnea. The pre-
Botzinger complex in the brainstem is thought to be the kernel of the CRO, but 
exposure of the pre-Botzinger complex to dichlorvos was not sufficient for apnea.  
Although OP induced central apnea was uniformly fatal, partial recovery of the CRO 
occurred post apnea with mechanical ventilation.   
 
 vi 
      Central apnea was ubiquitous in our rat poisoning model, but pulmonary 
dysfunction was extremely variable, with a range of pulmonary effects from fulminate 
pulmonary failure with prominent pulmonary secretions to no pulmonary dysfunction at 
all.  Vagal efferent activity is involved in neural control of pulmonary tissue but the 
vagus was not involved in OP-induced pulmonary dysfunction.  Anti-muscarinic 
medications are the mainstay of clinical therapy and are commonly dosed by their 
effects on pulmonary secretions.   Our studies found that atropine (the most common 
therapeutic agent for OP poisoning) resulted in a ventilation-perfusion mismatch 
secondary to effects on the pulmonary vasculature.   
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 1 
Study Background 
 
1.1 Significance of organophosphate poisoning 
 
Research exploring the pathophysiology of acute organophosphate (OP) 
poisoning is fragmented and incomplete with a body of clinical research divorced 
from a separate body of basic science, mechanistic research.  For example, 
respiratory failure following acute OP poisoning is most likely multi-factorial yet 
despite mechanistic research that implies both pulmonary dysfunction[1-3] and 
central apnea[4, 5], clinical research on respiratory failure focuses almost 
exclusively on the pulmonary effects[6-8] with little attention to the central effects.  
The research on the delayed symptoms following OP poisoning is even less well 
studied.  A 2008 report by the Research Advisory Committee on Gulf War 
Veterans’ Illnesses to the US Senate concluded a link between pesticides and a 
collection of neuro-behavioral changes called Gulf War Syndrome[9].  A wide 
range of neurological and psychiatric symptomatology has been linked to OP 
exposure[10-14] but research into the potential mechanisms involved is 
lacking[15].  Neurodegeneration[16, 17], reduced neurogenesis[18], alterations in 
sleep patterns[19, 20], downregulation of cholinergic receptors[21], alterations in 
other neurotransmitters[22], or seizure related neuropathology[23, 24] have all 
been proposed as explanations for post OP-exposure syndromes.  
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Despite the widespread use of OP pesticides for the last 60 years and the health 
problems they generate worldwide, the therapy for OP exposure has not 
changed significantly for the last 50 years.  Research into the best practice for 
treatment of OP intoxication has been lacking and we still do not know how the 
therapies identified decades ago should be used[25].  The evidence supporting 
many of the therapies used to treat OP exposure is weak and larger, better-
designed trials are needed[26].  The response of the public health, medical and 
scientific community to the problems involved with pesticide exposure has been 
called “inadequate”[27].  OP exposure is a health issue worldwide with an 
estimated 200,000 deaths per year globally from self ingestion alone[25].  
Despite intensive medical therapy, the mortality rate of OP poisoned patients in 
intensive care units ranges from 10-40%[6, 28-33].  Atropine, the core therapy for 
OP intoxication, has significant central nervous system[34] and pulmonary side 
effects[35] that may exacerbate OP toxicity, but even these mechanisms are not 
well understood.     
 
Understanding the complex pathophysiology of acute OP poisoning requires a 
comprehensive understanding of the physiologic changes that occur.  The lack of 
a detailed understanding of OP induced physiology is exemplified in “Rosen’s 
Emergency Medicine: Concepts and Clinical Practice, 6th edition,” the premier 
emergency medicine textbook.  The chapter on pesticides describes the 
respiratory failure following OP intoxication as secondary to diaphragmatic 
paralysis[36] with no discussion of the numerous other contributing mechanisms 
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(central apnea, upper airway obstruction, bronchospasm, pulmonary secretions, 
etc).  Previous attempts to describe the physiologic changes following OP 
poisoning have generally focused on a single organ system.  This simplistic 
approach is unlikely to succeed as, by their nature as neurotoxins, OP agents 
involve the CNS, peripheral nervous system and the organ system(s) of interest.  
In the real world situation where multiple organ systems interact, it is even more 
complicated.   Respiratory failure and pulmonary dysfunction have been 
identified as major mechanisms of mortality[6, 28], but little attention has been 
paid to central events that contribute to this dysfunction[37].  It is also possible 
that acute exposure to OPs may induce long-term changes in the central control 
of respiration through neuronal plasticity[38] where acute changes initiate long 
lasting effects in neuronal control.  
 
One of the basic tools missing in OP research is a detailed integrative 
physiologic model of OP poisoning to help understand the mechanisms of OP 
intoxication and how current and future therapies affect OP-induced changes.  In 
November of 2007 the US Department of Defense asked researchers for the 
“development, validation and use of animal models” to test new and existing 
therapies for weaponized organophosphate compounds[39].  A detailed 
understanding of how OP agents cause morbidity and mortality could help 
physicians better treat patients poisoned with this agent.   Future therapeutics will 
need to be developed using physiologic models to understand how the therapies 
affect mammalian physiology.  The lack of progress in the medical therapy of 
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acute OP intoxication and it’s sequelae can be directly related to the lack of a 
strong foundation in understanding the complex physiology of OP poisoning.   
 
1.2 Organophosphates and respiratory dysfunction 
 
Acute OP exposure produces a range of clinical findings related to increased 
acetylcholine levels centrally and peripherally acting on post-junctional receptors.  
For a list of findings and mechanisms of action see Table 1.1.  Some of these 
effects such as miosis are minor and will resolve over time.  Other effects such 
as increased pulmonary secretions escalate post exposure and have the 
potential to cause morbidity or even mortality if not adequately treated.  Still other 
effects such as central apnea are life threatening if not treated immediately.  
Many of the clinical effects of acute OP poisoning have the potential to cause 
respiratory dysfunction, and respiratory failure post OP exposure is most likely 
multi-factorial, but the exact mechanism of respiratory failure has not been 
determined. 
 
A number of synergistic mechanisms have the potential to contribute to 
decreased ventilation post OP exposure.  Acutely, peripheral acetylcholine at the 
neuromuscular junction induces fasciculation and weakness of voluntary muscle 
groups (including those involved in respiration)[40], and necrotic lesions within 
skeletal muscle cells[41].  Exposure of the neuromuscular junction to an OP 
results in dysfunction with repetitive compound muscle action potentials in 
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response to a single stimulus[42]. OP agents could also increase the work of 
breathing through an increase in lung static and dynamic compliance[43], 
constriction of the airways[37] or airway outlet obstruction[44].  Alternatively, OP 
agents could cause a central respiratory depression or central apnea[4, 45, 46]. 
 
Experiments exposing regions of the brain to OPs or cholinergic agonists 
demonstrate the potential of central mechanisms to contribute to OP-induced 
respiratory failure.  Exposure of the entire brain to increased acetylcholine via 
direct injection into the cerebrospinal fluid caused depressed respiration[47].  A 
more limited exposure of the ventral surface of the medulla in the region 
responsible for chemosensitivity caused a decrease in respiratory rate and 
volume[48].   Injection of a small volume (10-60nl) of a cholinergic agonist into 
the medial portion of the rostral pons (near the pontine reticular formation 
involved in REM sleep) also resulted in respiratory depression[49].  Interestingly, 
medullary slice experiments demonstrate that exposure of the pre-Botzinger 
complex (an area central to respiratory control) to acetylcholinesterase inhibitors 
had the opposite effect, increasing respiratory related output of the hypoglossal 
nerve[50].  The results of the medullary slice experiments have to be interpreted 
with caution as the respiratory network in these experiments lacks most of the 
connections present in an intact animal. 
 
Pulmonary physiology following OP exposure is complicated.  OP exposure to 
the lung results in increased acetylcholine at pulmonary muscarinic receptors 
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causing pulmonary dysfunction.  Airway changes from OP-induced 
bronchospasm[51] and bronchorrhea[52] result from both local and vagally-
mediated effects.   Total pulmonary vascular resistance, pulmonary arterial and 
pulmonary wedge pressure increase significantly in goats post OP exposure[51].  
Interstitial edema from OP exposure may contribute to decreased pulmonary 
compliance and ventilation perfusion mismatch[52, 53].  Clinically, patients with 
respiratory failure post-OP exposure demonstrate significantly impaired gas 
exchange despite anti-cholinergic medication and aggressive mechanical 
ventilation[6]. 
 
1.3 Anatomy and pathways involved in the central control of respiration 
 
To understand the potential effects of OP exposure on respiratory control, it is 
useful to review the neural pathways involved in the central control of respiration. 
Central control of respiration involves a series of components that allow the 
initiation and modulation of respiratory activity by the central nervous system.  At 
its most basic level the respiratory control system includes a central respiratory 
oscillator with both feedback and feed-forward afferent pathways for modulation 
as well as efferent pathways to components of the respiratory system.  Afferent 
signaling provides the environmental cues that allow accurate control of 
respiration in a changing internal and external environment.  Many parts of this 
control system contain cholinergic neurons that are affected during acute OP 
poisoning.  Understanding how the central and peripheral components of 
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respiratory control are integrated is critical to understanding how this system is 
affected by exposure to OPs.   
 
Respiratory neurons are concentrated in three distinct locations. Cat and rat 
animal models have been used extensively to map the connections between 
regions of the brain involved in respiratory control.   The dorsal respiratory group 
in the medulla is located in the dorsolateral nucleus tractus solitarius[54].  The 
ventral respiratory group is located in the ventrolateral medulla and is divided into 
three regions, caudal, intermediate and rostral.  The rostral ventral respiratory 
group contains the pre-Botzinger complex[55].  The pontine respiratory group 
(also called the pneumotaxic center) is located in the nucleus parabrachialis 
medialis and the Koliker-Fuse nucleus[56].  Other neurons involved in respiration 
are located throughout the brain and provide afferent input during respiration[57]. 
(see Figure 1.1) 
 
Afferent signaling to respiratory neurons in the pons and medulla projects from 
receptors within the lung.  Studies using rats have shown that pulmonary stretch 
receptors[58] and irritant receptors[59, 60] project via vagal afferents to modulate 
respiratory activity.  Activation of pulmonary stretch receptors cause reflexive 
cessation of respiration, known as the Hering-Breuer reflex[61].  Afferent inputs 
via irritant receptors (C-fibers) have a similar effect and activate of the cough 
reflex[62, 63].  Other irritant receptors (J receptors) initiate different changes in 
respiration with a reflexive tachypnea secondary to pulmonary edema[59].   
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Other afferent signaling originates from areas in the brainstem or higher brain or 
even areas outside the CNS.  Feed-forward signaling from the cerebral 
hemispheres[64] can modulate respiratory activity.  Both voluntary (breath 
holding) and involuntary (seizure related) activity can influence central respiratory 
control[64].  Sensory projections from the diaphragm[65], peripheral muscles[66] 
and the larynx[67] affect respiratory control as well.  Intercostal and abdominal 
muscle afferent activity suppresses central respiratory activity and phrenic nerve 
activity[68].  Projections from sites in the pons such as the pedunculopontine 
tegmental nucleus[69] involved in REM sleep and cerebellar structures[70] 
provide afferent signaling to the pneumotaxic center and apneustic center in the 
pons and the ventral and dorsal respiratory group in the medulla.    
 
Efferent signaling from the respiratory control center coordinates the cyclic 
activation of inspiratory and expiratory muscle groups and provides central 
control of some cardiovascular and pulmonary physiology.  Output from the 
central respiratory oscillator via the phrenic nerve triggers a major component of 
inspiration by stimulating a contraction of the diaphragm.  Spinal motor neurons 
innervate a range of muscles involved in inhalation and exhalation.  Additional 
efferent output via the hypoglossal nerve in a cat stimulates the muscles of the 
upper airway to prevent airflow obstruction during inspiration[71].   Other studies 
using rat, pig and cat models show that efferent signaling via the vagus nerve 
modulates ventilation via bronchial smooth muscle[72], pulmonary perfusion via 
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arterial smooth muscle[73, 74] and pulmonary secretions via pulmonary 
glandular output[75, 76].    
 
Although multiple brain regions may contribute to OP-induced central apnea [45, 
46], a number of sites are likely candidates due to their central role in respiratory 
control and their cholinergic innervation.  Cholinergic neurons do not seem to 
comprise a significant portion of the ventral respiratory group[77] but are located 
in the dorsal respiratory group[78] and the pre-ganglionic neurons of the vagus in 
the ventral medulla[79].  There are additional cholinergic ponto-medullary circuits 
involved in respiratory control[49, 80-82].  Any of these cholinergic circuits could 
be involved in OP induced central apnea.  A more detailed discussion of specific 
areas in the brain potentially involved in OP-induced apnea is below.   
 
1.4 Respiratory Pattern Generation 
 
Conceptually, the mechanism of OP-induced respiratory failure can be divided 
into two broad categories defined by location of action of the OP: 1) direct action 
of the OP on the central respiratory oscillator in the brainstem, 2) OP-induced 
feedback or feed-forward inhibition of the central respiratory oscillator.  
Regardless of the location of action of the OP, a loss of efferent output (phrenic 
output to the diaphragm) from the central respiratory oscillator is a critical feature 
of OP-induced apnea.  
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Rhythm and pattern generation in the brainstem involves synchronously active 
inhibitory and excitatory postsynaptic potentials producing fluctuations in the 
membrane potential of rhythm generating neurons.  The main inhibitory 
neurotransmitters involved in respiratory rhythm generation are glycine and !-
aminobutyric acid (GABA) with increased neurotransmitter release producing a 
depression in respiratory rate and phrenic nerve activity[83-85].  Excitatory amino 
acids required for respiratory rhythm generation include N-methy-D-aspartate 
(NMDA) and "-amino-3-hydroxy-5-methy-4-isoxazole propionic acid (AMPA) with 
NMDA primarily responsible for respiratory rhythm and AMPA responsible for 
pattern[86].   A number of different neurotransmitters are involved in modulating 
the respiratory rhythm generating elements of the respiratory neurons. 
 
The anatomic location of the central respiratory oscillator within the brainstem 
has been debated in the scientific literature but many experts now believe it is 
either the pre-Botzinger complex or the parafacial respiratory group (pFRG)[87, 
88].  One hypothesis is that a rhythm generator in the pFRG composed of pre-
inspiratory neurons periodically triggers output from an inspiratory oscillator in the 
pre-Botzinger complex [89].  Multiple lines of evidence support this hypothesis 
(see Onimaru et al[87] for a more detailed description) but alternative hypotheses 
exist.  A second hypothesis proposes that there are two interacting oscillators, 
the pre-Botzinger complex providing inspiratory activity and the pFRG providing 
expiratory activity.   A more detailed discussion of the data supporting this 
hypothesis was published by Feldman et al[88] in 2006.   
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1.5 Chemoreception and Respiratory Modulation  
 
Changes in chemoreception have been implicated as contributing to the 
respiratory changes from acute OP poisoning.  Chemoreception is a complex, 
redundant system that modulates respiratory activity to compensate for changes 
in pH, CO2 and O2.  Cholinergic transmission seems to be integrally involved in 
chemosensitivity but other nerves have a substantial role with some non-
cholinergic neurons directly sensing changes in pH and providing afferent input 
to the pre-Botzinger complex[90].    
  
The ventral surface of the medulla contains chemosensitive zones that sense 
changes in CO2.  Cells on the ventral surface of the medulla were previously 
thought to react to changes in pH in the cerebrospinal fluid secondary to 
dissolved CO2 [91] but more recently it is thought that intracellular pH and CO2-
specific receptors play a role[92].  Receptors responding to changes in PCO2 
within the central nervous system[93] provide afferent input via ponto-medullary 
circuitry[94].  Application of acetylcholine to the chemosensitive zone results in a 
stimulation of respiration[95] and cholinergic antagonists applied to this area[96], 
or introduced into the CSF[97], decrease CO2 sensitivity.  
 
It is unlikely that changes in chemosensitivity at the aortic or carotid bodies are 
involved in OP-induced apnea. Hypoxia increases ventilation secondary to 
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stimulation of receptors in the carotid body and aortic body. Glomus cells in the 
carotid body (and to a lesser extent the aortic body) detect changes in peripheral 
pH, PCO2[98], and PO2[99] and provide input to respiratory centers in the brain 
via the glossopharyngeal nerve.  The carotid body contains acetylcholine (and 
other neurotransmitters) that is thought to be released secondary to hypoxia-
induced activation of nicotinic receptors through concentration changes in 
adenosine[100].  Nicotinic receptors are present on chemoreceptor afferent fibers 
as well as on glomus cells (chemoreceptors).  Arterial chemoreceptor afferent 
activity in the rat increases excitatory drive through the release of glutamate at 
the nucleus tractus solitarius[101].  Theoretically, OP exposure with increased 
acetylcholine at the carotid body chemoreceptor afferent fibers would result in an 
increase in respiratory activity. 
 
1.6 Sleep and Respiratory Control 
 
Interestingly, there is a link between sleep and respiratory control that may be 
involved in OP-induced apnea. Changes in respiration occur during REM sleep 
with increases in respiratory rate and increased variability of breathing[102, 103].  
The onset of REM sleep is marked by increased activity of cholinergic pontine 
neurons in the laterodorsal tegmental and pedunculopontine tegmental nuclei 
(LTD/PPT)[104-106] with connections to respiratory neurons in the medulla[107, 
108].  Injection of cholinergic agonists into the region of the LTD/PPT induces a 
REM sleep like state with respiratory depression characterized by decreased 
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tidal volumes and respiratory rate[109].  This suggests a connection between the 
LTD/PPT and the rhythm generating cells in the brainstem. The respiratory 
effects of LTD/PPT afferent activity may be indirect via the reticular formation as 
there is a close correlation between mid-brain reticular formation sleep specific 
activity and respiratory efferent activity[110].   
  
1.7 Pulmonary function 
 
A wide range of pulmonary activities are mediated by post-junctional effects of 
acetylcholine, providing the underlying mechanisms for OP-induced pulmonary 
dysfunction.  Postganglionic parasympathetic nerve endings form a meshwork 
around the airways and vessels of the lungs.  Acetylcholine is accumulated in 
synaptic vesicles at the post-synaptic nerve terminals and depolarizing of the 
nerve terminal causes release of acetylcholine into the synaptic cleft, where it 
diffuses to interact with both pre- and post-synaptic receptors.  Depending on the 
animal species, cholinergic stimulation of muscarinic receptors plays a role in the 
stimulation of mucus secretions[111] as well as the secretion of both water and 
electrolytes[3].  Two cholinergic mechanisms in rabbits compete for modulating 
pulmonary vascular tone, a direct stimulatory effect and an indirect endothelium-
dependent (nitric oxide) relaxing effect[112, 113].  Acetylcholine also induces 
bronchial smooth muscle constriction, regulating bronchial airflow by narrowing 
the airway diameter[114].  Airway smooth muscle contraction is induced by 
muscarinic receptors (M2 and M3)[115, 116]. 
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Bronchoconstriction is a common complication of acute OP poisoning.  Acute 
changes in pulmonary airflow is regulated primarily by bronchial airway caliber 
that can be controlled via efferent signaling or local pathways.  Stimulation of 
adrenergic sympathetic fibers causes dilation of bronchial smooth muscle while 
stimulation of cholinergic parasympathetic fibers causes constriction.  Vagal 
efferent signaling results in bronchoconstriction mediated by substance P (in 
rats) [72] and acetylcholine (in dogs)[114] acting on bronchial smooth muscle.  
Effects from a variety of local compounds mediate changes in bronchial tone with 
compounds such as acetylcholine, histamine, serotonin, leukotrienes, !-
adrenergic agonists and others mediating bronchoconstriction[2, 117-119] and 
compounds such as ß2-agonists, nitric oxide, and others mediating 
bronchodilatation[119, 120].  
 
A number of different mechanisms may be involved in OP-induced dysfunction in 
pulmonary gas exchange.  Efficient pulmonary function requires a coordination of 
ventilation and perfusion to allow the transfer of oxygen and carbon dioxide 
between the airways and the pulmonary vasculature.  Pulmonary perfusion is 
normally matched to ventilation via local and neural mechanisms but the 
coordination of these mechanisms during pathologic states is not completely 
understood.  In general, sympathetic stimulation increases pulmonary vascular 
resistance while parasympathetic stimulation results in a decrease.  Stimulation 
of vagal efferents in the cat results in vasodilatation mediated by acetylcholine 
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acting on the vascular smooth muscle[74].  Rat pulmonary vascular tone was 
increased with stimulation of cervical and thoracic (C7-T4) spinal 
sympathetics[121].  Local prostaglandins (PGE2, PGF2!), thromboxane, 
angiotensin II, !-adrenergic agonists increase pulmonary vascular 
resistance[122-125].  Local agents such as PGE1, prostacyclin, nitric oxide, 
bradykinin mediate a decrease[124, 126, 127] but it is unclear how these 
mediators are coordinated.  Pulmonary arterial caliber is also moderated by local 
hypoxic conditions via production of local mediators from endothelial cells[122, 
126, 128].   It is most likely that OP-induced decrease in pulmonary gas 
exchange is related to an inappropriate decrease in pulmonary vascular tone. 
 
Increased pulmonary secretions are a prominent feature of acute OP exposure.  
Tracheal and pulmonary secretions are enhanced by local mediators and via 
central nervous system pathways.  In cats, irritant compounds can induce 
increased pulmonary secretions via both methods[129].  Vagal efferent activity 
provides most of the regulatory control of output from airway glands via 
acetylcholine, substance P, and vasoactive intestinal peptide (VIP).  In piglets, 
reflexive increase in tracheal secretions occurs secondary to stimulation of 
laryngeal mucosa and pulmonary C-fibers [130].  Local mediators such as 
substance P can increase secretory output in the absence of neural control. 
 
The effect of OP exposure on interstitial fluid has not been well studied.  
Changes to the interstitial compartment of the lung are mediated by locally 
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secreted compounds and neural efferent activity. The release of a wide range of 
inflammatory mediators from rat and rabbit airway epithelial cells[131-134], 
human mast cells[117] and human and mouse inflammatory cells[135-137] are 
modulated by cholinergic mechanisms.  Systemic or local hypoxic conditions 
mediate changes in the vascular epithelium of rats resulting in increased 
permeability[138].  Other injuries such as sepsis[139], aspiration[140] or 
trauma[141] can cause similar changes.   Pulmonary edema increases 
pulmonary and bronchial C-fiber afferent activity[142], causing reflexive 
vasodilatation[143], increased mucous secretion, bronchoconstriction, and 
changes in respiratory rate and volume[138, 144] in animal models. 
 
Acute OP poisoning results in conflicting signaling from stimulatory and inhibitory 
cholinergic pathways involved in both central respiratory control and neural 
control of the lung.  OP agents increase acetylcholine levels in all areas of the 
brain[145] and lung[37], but it is not clear which area (or group of areas) are 
responsible for OP-induced respiratory failure.    
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Table 1.1 – Mechanisms of action of organophosphate poisoning 
Finding Mechanism of Action 
Diarrhea/GI cramps Cholinergic stimulation of colonic smooth muscle and 
decreased fluid absorption predominantly via muscarinic 
receptors [146-149] 
Urination Cholinergic stimulation of bladder smooth muscle muscarinic 
receptors[150, 151] 
Miosis Cholinergic stimulation of iris smooth muscle tone[152] 
Bradycardia Cholinergic stimulation of cardiac receptors[153], the 
nucleus tractus solitaris[154] or reflex bradycardia from 
increased sympathetic nerve activity[155] 
Tachycardia Cholinergic stimulation of receptors in the sympathetic 
ganglia and adrenal medulla with release of catecholamines 
[156] 
Bronchorrhea/Pulmonary 
Secretions 
Cholinergic stimulation of pulmonary goblet cells and glands 
[3, 111] or reflex bronchorrhea from pulmonary afferent 
activity via the nucleus of the solitary tract[157] 
Bronchoconstriction Cholinergic stimulation of bronchial smooth muscle[115, 116] 
or reflex bronchoconstriction from pulmonary afferent activity 
via the nucleus of the solitary tract[157] 
Emesis Cholinergic stimulation of stomach smooth muscle and 
gastric secretion via muscarinic receptors [146, 158, 159] as 
well as brainstem triggered “motion sickness” with nausea 
and vomiting[160]  
Lacrimation Cholinergic stimulation of lacrimal glands[161] 
Salivation Cholinergic stimulation of salivary smooth muscle[162] and 
exocytotic secretion[163, 164] 
Fasciculations Cholinergic stimulation of skeletal muscle fibers[42, 165] 
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Figure 1.1 – Afferent inputs to respiratory centers in the brainstem 
 
CENTRAL NERVOUS SYSTEM  
1) Cerebral Hemispheres – conscious thought and seizure related feed-
forward inputs 
2) Latero-dorsal Tegmental/Pedunculopontine tegmental (LDT/PP)– sleep 
related respiratory changes 
3) Fastigial Nucleus –changes in CO2 levels, relay of vagal afferent inputs, 
4) Ventral Medullary Surface –changes in CO2 levels  
CRANIAL NERVES 
1) Glossopharyngeal Nerve – changes in arterial O2, CO2 and pH 
2) Vagus Nerve – pulmonary mechanoreceptors and irritant input 
SPINAL NERVES 
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1) Peripheral sensory – stretch receptors in diaphragm and peripheral 
muscles 
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Chapter 2 - Pathophysiology of respiratory failure following acute dichlorvos 
poisoning in a rodent model. 
 
Previously published - Gaspari RJ, Paydarfar D. Pathophysiology of respiratory 
failure following acute dichlorvos poisoning in a rodent model. Neurotox. 2007 
28(3) p664-71. 
 
 
2.1 Abstract  
OP poisoning causes a cholinergic crisis with a wide range of clinical effects 
including central apnea, pulmonary bronchoconstriction and secretions, seizures, 
and muscle weakness. The morbidity and mortality from acute OP poisoning is 
attributed to respiratory failure but the relative contributions of the central and 
peripheral effects in producing collapse of the respiratory system are unclear.  In 
this study we used a novel adult rat model of acute OP poisoning to analyze the 
pathophysiology of acute OP poisoning.  We found that poisoning caused rapidly 
lethal central apnea. In animals sustained with mechanical ventilation, we found 
that following central apnea there ensued progressive pulmonary insufficiency 
that was variable in timing and severity.   Our findings support the hypothesis that 
OP poisoning in this animal model causes a sequential ‘‘two hit’’ insult, with rapid 
central apnea followed by delayed impairment of pulmonary gas exchange with 
prominent airway secretions. 
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2.2 INTRODUCTION 
OP poisoning produces a cholinergic crisis by inhibition of acetylcholinesterase in 
the central and peripheral nervous systems.  Acute effects of poisoning include 
central apnea [4, 46, 48, 166], seizures [167, 168], bronchorrhea, 
bronchoconstriction, muscle weakness, miosis, urination, and salivation [37, 52, 
169, 170].  The morbidity and mortality from acute OP poisoning is attributed to 
respiratory failure [171] but the relative contributions of the central and peripheral 
effects in producing collapse of the respiratory system [172] are unclear.  The 
clinical literature emphasizes the peripheral effects contributing to acute 
pulmonary insufficiency [28, 171]. However this does not exclude early mortality 
in the field due to central apnea [173, 174]. 
 
In this study we used a rodent model to analyze the dynamics of respiratory and 
cardiovascular collapse during acute OP poisoning. We found that poisoning 
caused a rapidly lethal central apnea. Central apnea consistently occurred soon 
after the poisoning but pulmonary insufficiency was more variable in both timing 
and severity.  Mortality was reduced in animals that were sustained solely by 
artificial ventilation; however most ventilated animals exhibited signs of impaired 
gas exchange due to pulmonary insufficiency.  Our findings support the 
hypothesis that OP poisoning in this animal model causes a sequential “two hit” 
insult, with rapid central apnea followed by delayed impairment of pulmonary gas 
exchange with prominent airway secretions. 
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2.3 MATERIALS AND METHODS 
 
We studied 27 male Wistar rats, weighing 275-325 gm (Charles River 
Laboratories, Wilmington, MA). The University of Massachusetts Medical School 
Institutional Animal Care and Utilization Committee approved all experimental 
procedures and protocols.  The animal model used in this study is a novel 
preparation for OP research and the procedures are described in detail below. 
 
Surgical Procedures 
Surgical procedures were performed under general anesthesia with 1.5 – 2.2% 
isoflurane (Abbott Labs, North Chicago, IL) titrated to achieve a respiratory rate 
of 50-60 breaths per minute (bpm).  All surgical procedures were performed 
under 100% oxygen.  The animals were restrained in a supine position with the 
head extended and limbs abducted.  Adequacy of anesthesia was confirmed by 
lack of withdrawal from a painful stimulus applied to the foot.  The trachea was 
cannulated percutaneously via a tracheostomy using polyethylene (2.4mm) 
tubing.  Polyethylene  (0.5 mm) tubing was inserted into the femoral artery for 
blood pressure recordings and into the femoral vein for intravenous access.  
Bladder catheterization was unnecessary because the experiments lasted less 
than 2.5 hours. Spontaneous urination was used as a marker of cholinergic 
toxicity. 
 
Anesthetic Circuit 
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Spontaneously breathing animals received oxygen and anesthetic through a 
3/32” kynar barbed y-fitting (Small parts INC, Miami Lakes, FL) with one arm 
supplying the gas mixture and the other arm attached to a low-pressure gas 
scavenger system (Surgivet, Waukesha, WI).  The distal y-tube was attached in-
line with a CO2 detector, a small chamber pneumotachometer, and the tracheal 
tube.  The dead space of the ventilation circuit (y-tube, end-tidal CO2 detector, 
pneumotachometer, and tracheal tube) was 0.33 cc total or roughly 10% of the 
tidal volume of the animals.   All animals that were not mechanically ventilated 
received 100% oxygen throughout the course of the experiment. 
 
Some animals received mechanical ventilation with or without pharmacologic 
paralysis.  Mechanical ventilation was supplied through a modification of the 
above anesthesia circuit using a small animal positive-pressure ventilator 
(Harvard Apparatus, Holliston MA).  Once the surgical procedures were 
completed the fraction of inspired oxygen was titrated to achieve a partial arterial 
oxygen concentration (PaO2) of 100-115 mmHg.  The ventilator was initially set to 
a tidal volume of 3 cc and respiratory rate of 80 bpm.  Ventilator settings were 
adjusted to achieve a target end-tidal PCO2 < 60 mmHg.  Once these targets 
were achieved the ventilator and the fraction of inspired oxygen settings were not 
changed throughout the experiment.  In pharmacologically paralyzed animals, 
adequacy of paralysis was monitored using esophageal pressure recordings (see 
below) to monitor respiratory effort. 
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Recording Techniques 
Respiratory Recordings 
Expired CO2 was measured using an infrared CO2 sensor (Novametrix, 
Wallingford CT) in-line with the endotracheal tube. End-tidal pCO2 (PETCO2) was 
recorded as the maximum expired pCO2 for each respiratory cycle, along with 
airflow, respiratory rate, volume of expired air, and minute ventilation.  Airflow 
was measured using a small chamber pneumotachometer (HSE, March-
Hugstetten Germany) in series with the expired CO2 detector. The volume of 
expired gas was calculated using half-wave integration of the airflow signal from 
the pneumotachometer.  Respiratory rate was calculated using the peak of the 
inspiratory tracing as a marker of a single breath.  Minute ventilation was 
calculated as respiratory rate multiplied by the volume of expiration.  The normal 
respiratory rate of the rat is 80 bpm.  For the purpose of the study, we defined 
apnea was as cessation of airflow for greater than 20 seconds and central (or 
non-obstructive) apnea as concomitant cessation of respiratory effort and airflow 
for greater than 20 seconds.  Oxygen saturation was measured using a 
photodetector (Nellcor, Pleasanton CA) placed on the right paw.  Raw tracing of 
the oxygen saturation signal as well as measured value of the arterial oxygen 
saturation were recorded and displayed continuously.  Respiratory effort was 
monitored by esophageal pressure via a saline filled open tube inserted to the 
level of the mid-thorax connected to a pressure transducer (Cobe, Lakewood 
CO).  Prior studies have correlated this esophageal pressure recording with 
pleural pressure as a non-invasive measurement of respiratory effort [175].  
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Pressure recordings were calibrated relative to atmospheric pressure recorded at 
the level of the animal’s mouth immediately prior to insertion of the esophageal 
tube. Respiratory effort was measured as maximal negative esophageal pressure 
from baseline for each respiratory cycle during spontaneous respiration.  Similar 
measurements were performed during positive pressure mechanical ventilation 
as the negative deflections of respiratory effort were easily distinguished from the 
positive deflections of positive pressure ventilation.   
 
Hemodynamic Recordings 
Blood pressure and pulse rate were measured using polyethylene tubing 
connected to a pressure transducer (Utah Medical, Midvale UT).  Mean arterial 
pressure was calculated from the analog signal.  Pulse rate was calculated using 
peak systolic blood pressure of the arterial pressure tracing as the marker for a 
single heartbeat.  For the purpose of this study death was defined as an arterial 
pulse pressure (systolic pressure minus diastolic pressure) less than 3mmHg 
with a systolic blood pressure less than 5mmHg. 
 
Arterial Blood Gas Measurements 
Arterial blood samples for blood gas measurements were obtained via a 
stopcock attached in-line with the femoral arterial line.  An initial small amount of 
blood (0.1 cc) was withdrawn and discarded to prevent mixing of catheter saline 
flush and arterial blood.  A 0.2 ml sample of arterial blood was then withdrawn for 
immediate analysis in a Rapidlab 248 blood gas analyzer (Bayer Healthcare, 
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East Walpole MA).  Samples were withdrawn at differing schedules depending 
on the study protocol.  In groups with spontaneously breathing animals 
measurements occurred sporadically.  In groups with mechanical ventilation 
measurements either occurred at regular intervals (ventilation throughout) or at 
the time of apnea (rescue ventilation).  Alveolar-arterial gradients (A-a) were 
estimated using the following formula, where all pressures are in mmHg. 
 
Estimated A-a gradient = (Fraction of inspired oxygen (%)/100) x (Patm – 47) – 
(PaCO2/0.8) – PaO2 
 
A-a gradients were reported as a percentage of the average A-a gradient during 
the control period for each animal. 
 
Recordings in Unanaesthetized Animals 
Unanaesthetized animals were placed in a cylindrical restraining device with an 
attached nose cone (Kent Scientific, Torrington CT).  Oxygen was supplied 
through a pneumotachometer and end-tidal CO2 detector (see above) attached 
to the nose cone.  The nosecone was retracted down the restraint device until a 
seal was formed around the animal’s nose.  An adequate seal was determined 
by the strength of the airflow signal through the pneumotachometer.  A needle 
attached to a length of polyethylene tubing was placed subcutaneously through 
an access port of the restraint device to allow a subcutaneous injection once the 
animal was restrained.  This was accomplished under anesthesia at least 30 
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minutes prior to initiating the experiment to minimize respiratory changes 
associated with the needle insertion. 
 
Animals were habituated to the restraining device in a dark quiet environment at 
least 30 minutes prior to beginning the experiment.  No invasive procedures such 
as those required for hemodynamic monitoring were performed.  The animal was 
removed from the restraining device once airflow through the pneumotachometer 
ceased and the animal appeared motionless. Visual inspection of the animals 
outside of the restraint device allowed us to determine if the lack of airflow was 
secondary to apnea or from dislodgement of the animal’s nose from the 
nosecone apparatus. 
 
Signal Conditioning and Data Acquisition System 
All physiologic recordings were measured continuously over the course of the 
experiment using a PC (Dell, Round Rock, TX) and data acquisition system (ADI 
instruments, Colorado Springs CO). Physiologic data were sampled at 400 Hz 
and displayed continuously during the experiment, and subsequently averaged in 
15-second bins. Measured and calculated physiologic values were displayed in 
real time.  Airflow and esophageal pressure were amplified and filtered 
(Molecular Devices, Sunnyvale, CA) prior to recording and display by the data 
acquisition system.  Arterial pressure was amplified and filtered using a separate 
amplifier (ADI Instruments) controlled by the data acquisition system.  
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Protocol and Data Analysis 
Animals were allowed to reach a physiologic steady state for 15 to 30 minutes 
following the surgical procedures prior to initiating poisoning. Dichlorvos (Sigma-
Aldrich, St Louis MO) was diluted in 0.9% saline from a stock solution in 
acetonitrile and administered at a dose of 100 mg/kg subcutaneously (roughly 3x 
LD50) in all groups.  Physiologic recordings were continued until blood pressure 
and pulse rate declined to the study endpoint.   The study was terminated at 
death or 1 hour, whichever came first.     
 
Animals were randomized to four groups (Table 2.1). Animals in Group I (10 
animals) were anesthetized and breathed 100% oxygen spontaneously.  Animals 
in Group II (7 animals) were anesthetized.  They initially breathed spontaneously 
but received mechanical ventilation that was initiated when the animal developed 
apnea, as defined by a lack of airflow and concomitant absence of respiratory 
effort.  The fraction of inspired oxygen was titrated during the control period to 
achieve a PaO2 of 100-115 mmHg, and was not changed throughout the 
remainder of the experiment.  Arterial blood gases were measured at three times 
on surviving animals: prior to the poisoning (control), at point of apnea and later 
during mechanical ventilation.  
 
Animals in Group III (6 animals) were anesthetized, pharmacologically paralyzed 
and mechanically ventilated throughout the experiment.  Adequacy of anesthesia 
was determined prior to paralysis and anesthesia was maintained at a constant 
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level pre- and post- paralysis.  Animals were paralyzed with gallamine 
hydrochloride, a nicotinic and M2 muscarinic antagonist (Sigma-Aldrich, St Louis 
MO) (6.2 mg/kg bolus and 9.3 mg/kg continuous venous infusion) and allowed to 
reach a physiologic steady state prior to initiating the research protocol.  Inspired 
oxygen concentration was titrated to a target PaO2 concentration of 100-
115mmHg prior to the poisoning as described above. Arterial blood gases were 
measured every 3 minutes for the first 24 minutes (8 times) followed by every 6 
minutes for the next 42 minutes (7 times).   
 
Animals in Group IV (4 animals) were poisoned while unanaesthetized and 
spontaneously breathing.  100% O2 was supplied through the nose cone and 
recording apparatus during the entire experiment.  Respiratory recordings were 
obtained from an in-line pneumotachometer and end tidal CO2 detector attached 
to the nose cone.  The animals were removed from the restraining device 
following apnea and observed for 30 minutes to detect any resumption of 
sustained respiratory activity.   
 
Statistics 
Cardiorespiratory effects of dichlorvos poisoning are expressed in the text as 
mean + standard error of the entire cohort unless otherwise specified.  Between-
group comparisons were performed using an unpaired Student’s t-test or Fisher’s 
Exact test where appropriate [176].  P values are presented at p=ns for all p 
values greater than 0.1.
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2.4 RESULTS 
 
Cardiorespiratory parameters during the control period showed no substantial 
difference between Group I and the other anesthetized Groups (II and III) (see 
table 2.2) with the exception of PETCO2 and tidal volume.  Group III animals were 
paralyzed and mechanically ventilated which precludes measurement of 
respiratory rate, tidal volume and effort.  However data from end-tidal CO2, blood 
pressure, and pulse rate were included. PETCO2 levels were slightly lower in 
Group I, corresponding to slightly higher tidal volumes most likely due to lower 
levels of anesthesia.  These small differences did not affect respiratory effort or 
time to apnea (see below).  
 
Animals in Group I demonstrated a central apnea characterized by a 
simultaneous loss of tracheal airflow and respiratory effort prior to circulatory 
collapse with respiratory rate decreasing prior to the point of apnea.   Figure 2.1 
shows representative recordings from one animal.  Animals in Group I showed 
an average respiratory rate that began declining 1 minute after poisoning and 
reached apnea an average of 4.95 min  (+1.55 min) post-poisoning.  
Hemodynamic variables were robust over 20 minutes longer, gradually declining 
to the study endpoint (see Materials and Methods).  Figure 2.2 plots respiratory 
rate and blood pressure over time for Group I and Group II.  At the time of apnea 
the average mean arterial pressure (90 + 10mmHg) was in the normal range and 
there was no systemic hypoxia (oxygen saturation >95%).  A-a gradients 
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measured at this time were also in the normal range for a rat.  Animals who 
received mechanical ventilation (group II and III) lived longer then animals with 
no intervention (group I) but mechanical ventilation did not prevent all mortality 
(Figure 2.3).   
 
Animals in all groups that survived the initial apnea showed signs of pulmonary 
insufficiency.  Animals in Group II (rescue mechanical ventilation) and group III 
(mechanical ventilation throughout) showed a significant increase in survival at 
one hour post poisoning (69.2% vs. 0%).  The animals that did not survive 
despite mechanical ventilation were unable to be ventilated and uniformly had 
fluid filling their tracheal tube at the time of death.   Markers of pulmonary 
dysfunction such as A-a gradient  (-1.3 vs 62.0) and changes in the VE/VI ratio 
(28 vs 66%) were significantly worse in animals that died (Figure 2.4). 
 
During normal mechanical ventilation the (VE)/(VI) ratio is expected to be close to 
one.  Mechanical ventilation supplies a constant VI so a reduction in this ratio is a 
result of decreased VE possibly due to severe loss of pulmonary compliance or 
outright obstruction of the lower airways resulting in a rupture of the tracheal 
seal, thereby causing a reduction in expired volume compared to inspired 
volume.  Barotrauma would also result in a change in the (VE)/(VI) with leak of air 
into the chest cavity, but this is less likely as none of the animals showed 
pulmonary dysfunction without secretions filling the tracheal tube.  Future studies 
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using this animal model could benefit from measurement of airway pressure, 
which we would expect to increase due to pulmonary toxicity of OP[43, 52].  
 
Arterial blood gas measurements in Groups II and III showed that the pulmonary 
effects of the OP were variable. Comparing animals that lived with those that 
died despite mechanical ventilation shows a difference between the two groups.  
In animals that did not survive to the study endpoint the A-a gradient began 
increasing around the point of apnea and progressively worsened during the 
post-apneic period.  Two of the 6 animals with mechanical ventilation throughout 
the experiment (Group III) died before 1 hour with secretions filling the tracheal 
tube (Figure 2.5A).  One of these animals showed increasing A-a gradients 
starting around the projected point of apnea.  The other animal showed a normal 
A-a gradient at the time of death but a VE/VI ratio < 0.2.  Arterial blood gas 
measurements in animals in Group II (rescue ventilation) showed that abnormal 
pulmonary gas exchange began around the time of apnea. The animals showed 
an elevated A-a gradient over baseline around the time of apnea (35mmHg +/- 
15) with some animals (2 of 7) demonstrating a widening A-a gradient that 
culminated in death from a fluid filled trachea (figure 2.5B).  Animals that lived to 
one hour (5 of 7) demonstrated abnormal A-a gradients at the point of apnea 
(33mmHg) but normal A-a gradients at the termination of the experiment 
(1mmHg). The change in A-a gradient (Group II and III) was variable with 
animals that did not survive demonstrating a significant increase in A-a gradient 
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over those that lived to the study endpoint (63 vs. -1.3 mmHg, p=0.0004 Figure 
4).  
 
Anesthesia had a limited effect on the characteristics of the apnea following 
acute OP poisoning.  None of the animals in Group IV (no anesthesia) survived 
and the time to respiratory arrest occurred over a similar time course as in Group 
I animals (4.0 min vs. 4.95 min, p=ns).   
 
Some animals in Group I (7 of 10) demonstrated auto-resuscitative breathing 
post apnea.  Although some authors use gasping and auto-resuscitative 
breathing interchangeably[177], we use the term to refer to post apneic breathing 
that supports cardio-pulmonary activity[178].  The post-apneic breathing was 
characterized by a weak respiratory effort at 20 bpm that occurred once blood 
pressure dropped close to the study endpoint.  Animals with autoresuscitative 
breathing showed a prolonged time to circulatory collapse (31 vs. 12 minutes, 
p=0.025).   Post-apneic respiratory activity was not seen in any of the other 
groups.  It should be noted that Group III animals were paralyzed so post-apneic 
respiratory activity would not have been recognized and Group IV animals were 
removed from the restraining device (which also recorded breathing) shortly after 
apnea onset precluding any record of late respiratory activity.  Visual observation 
of animals removed from the restraining device showed no resumption of 
respiratory activity. There was no visible respiratory effort once animals were 
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removed from the restraint device.  The end point for Group IV was respiratory 
arrest rather than circulatory collapse since arterial pressure was not recorded. 
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2.5 DISCUSSION 
 
In our animal model of acute OP poisoning, dichlorvos at 3 times the LD50 
caused a central failure of breathing in all animals. The key finding was rapidly 
progressive bradypnea leading to apnea due to loss of respiratory effort. 
Respiratory muscle weakness is an unlikely mechanism of respiratory failure 
because apneic animals exhibited retching, intermittent flexing of the torso, and 
gasping respirations during the post apneic period.  The retching, commonly 
seen in OP poisoning, was identified as strong positive deflections of the 
esophageal pressure transducer.  Although other muscular activities such as 
forced exhalation, thoracic wall contraction or abdominal wall contraction would 
increase esophageal pressure; all of these activities are accompanied with 
tracheal airflow, which was not seen during retching.  Esophageal contractions 
cause increased esophageal pressure without tracheal airflow but differentiating 
this from retching would require esophageal and gastric electromyelograms.  
 
The lack of paralysis of the respiratory muscles is also supported by other 
studies that demonstrated intact diaphragmatic contraction following OP 
poisoning [46].  We excluded systemic hypotension as a cause of central apnea 
because arterial pressure was in the normal range at the time of apnea onset.  
We also excluded apnea due to acute upper airway obstruction since this would 
have manifested as increasing respiratory effort during apnea, whereas in all our 
experiments hypopnea and apnea were associated with reduction followed by 
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absence of respiratory effort, respectively. Our findings are consistent with other 
studies of OP poisoning in experimental animal models that demonstrate loss of 
central inspiratory drive due to poisoning [45, 46, 168].  
 
Central apnea has not been documented in clinical studies; rather case series of 
human OP poisoning emphasize respiratory failure due to toxic cholinergic 
effects on the lung [7, 28, 29, 179].  It is possible that central apnea is not 
prevalent in the clinical literature because either it is masked by mechanical 
ventilation or patients with central apnea die before reaching the hospital.  
Another possibility is that the human central respiratory oscillator is resistant to 
cholinergic toxicities.  It is less likely that the lack of central apnea is due to 
ingestions less then the LD50.   There are limited data concerning the degree of 
most exposures due to circumstances of the ingestion (suicide, accidental 
exposure…) but the published survival rate post severe OP-poisoning averages 
30% despite aggressive anti-cholinergic therapy and supportive care.  Anti-
cholinergic therapy is considered very effective and aggressive therapy in 
patients who ingested the LD50 of an OP would likely be less than 30%. 
 
The mechanism of central apnea from increased acetylcholine remains unclear.  
Peripheral feedback to the central respiratory oscillator, feed-forward inhibition to 
the central respiratory oscillator, disruption of ponto-medullary circuits or 
disruption of the central respiratory oscillator itself all remain possibilities. Inputs 
such as the vagus nerve, glossopharyngeal nerve or ponto-medullary inputs may 
 37 
be involved.  Mechanoreceptors in the lung that could be activated by 
bronchoconstriction or fasciculations provide feedback to the CRO and can result 
in apnea [54].  Acetylcholine receptors have been shown to be active in 
modulating respiratory rhythm [50] and over-stimulation may result in loss of 
rhythmic output of the CRO.  Further studies are needed to address the primary 
source of central inspiratory inhibition due to cholinergic excess. 
 
The second phase of the OP poisoning, progressive pulmonary insufficiency, 
was variable across animals. Although all poisoned animals exhibited signs of 
pulmonary compromise, with either reduction in VE/VI ratio and/or widening of the 
alveolar-arterial gradient, the degree of pulmonary dysfunction was highly 
variable and only one third of the animals died from pulmonary secretions filling 
their lungs.  It is unclear what factors led to this variability but it is interesting to 
note that the percentage of animals dying from the pulmonary secretions (33%) 
is similar to the percentage of human patients that die despite intensive care (10-
35%) [28, 29].   We would speculate that this variability is related to a threshold 
effect for each individual rat where a certain amount of local stimulation of irritant 
fibers is needed to create enough secretions and interstitial edema to perpetuate 
stimulation of pulmonary irritant fibers.  This would be dependent on individual 
animal responses to the local irritation and could result in a stimulatory feedback 
loop with overwhelming pulmonary secretions.  Further studies are needed to 
determine the mechanisms involved in OP-induced pulmonary dysfunction. 
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Gasping respirations were recorded in some poisoned animals that lived on 
average almost 20 minutes longer then animals that showed no gasping 
respiration.  However it is unlikely that the gasping respirations prolonged life 
because the respiratory activity occurred almost immediately before the point of 
death with mean arterial pressures averaging around 10 mmHg at the time of 
gasping. Prior studies of gasping have noted an association of gasping activity 
with hypoxia [180] but this was not consistently found in our study as hypoxia 
greatly preceded gasping in many of the animals. 
 
Extrapolation of these results to the clinical treatment of human OP poisonings 
should be done with extreme caution but there are two aspects of our data that 
deserve discussion.  Apnea occurred significantly prior to cardiac arrest so that in 
battlefield areas where triage is important, individuals in respiratory arrest may 
survive for a period of time prior to ventilatory support.  Studies of patients who 
survive the initial stages of acute OP poisoning to make it to the intensive care 
unit describe long periods of treatment requiring anticholinergics [7, 28, 29] but 
as discussed above, this patient population may not be identical to patients 
encountered in the pre-hospital setting or a mass casualty event.  Patients 
encountered immediately after a poisoning may show a precipitous collapse of 
respiratory effort.  Despite aggressive anticholinergic therapy and intensive 
supportive care, severe OP poisonings show a mortality rate around 30%[7, 28]. 
These patients eventually die due to inability to maintain oxygenation despite 
ventilation or inability to maintain adequate perfusion[28]. 
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A potential problem with our model is the use of inhaled anesthetics.  Inhaled 
anesthetics have a well-documented effect of respiratory depression.  It could be 
argued that the apnea seen in our study was secondary to the inhaled anesthetic 
and not the OP itself.  If isoflurane was wholly or partially responsible for the 
apnea in our experimental model then we would have found a significant 
differences between the outcome of Group IV (unanaesthetized animals) and 
that of Groups I and II.  Both anesthetized and unanaesthetized groups showed 
100% mortality with no differences in the time to onset of apnea. 
 
An additional potential problem relates to the use of gallamine as a paralytic 
agent in mechanically ventilated animals.  Gallamine is a known antagonist of 
muscarinic agonists and acts non-competitively via allosteric binding of M1 and 
M2 muscarinic receptors in the brain and lung [181, 182].  Both M1 and M2 
receptors are present in the pre-Botzinger complex [183] but gallamine has been 
used extensively in respiratory research and has no effect on the output of the 
CRO [184].  In previous studies gallamine has resulted in potentiation of vagally 
mediated bronchoconstriction [185] and could theoretically increase pulmonary 
secretions following acute OP exposure. It is important to note that there were no 
pulmonary effects of gallamine during the control period prior to the poisoning, as 
determined by A-a gradient and VEVI ratio.  Future studies in this model should 
be performed with neuromuscular blocking agents that have no effects on 
muscarinic receptors. 
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Table 2.1 – Interventions for Experimental Groups  
 
 Group I (n=10) Group II  
(n=7) 
Group III  
(n=5) 
Group IV  
(n=4) 
Anesthesia Isoflurane Isoflurane Isoflurane None 
FIO2 during 
experiment 
100%  Titrated to PAO2 
of 100-115mmHg 
Titrated to 
PAO2 of 100-
115mmHg 
100% 
Pharmacologic 
Paralysis 
None None Gallamine None 
Mechanical 
Ventilation 
None At apnea Throughout 
experiment 
None 
1hour survival 0/10 5/7 4/6 0/4 
Functional 
Measurements 
ETCO2, Vi, Ve,  
esophageal 
pressure, arterial 
pressure, oxygen 
saturation, PaO2, 
PaCO2 
ETCO2, Vi, Ve,  
esophageal 
pressure, arterial 
pressure, oxygen 
saturation, PaO2, 
PaCO2 
ETCO2, Vi, Ve,   
arterial 
pressure, 
oxygen 
saturation, 
PaO2, PaCO2 
ETCO2, Vi, Ve 
 
FIO2 - fraction of inspired oxygen 
ETCO2  - end tidal carbon dioxide 
Vi - volume of inspired gas 
Ve – volume of expired gas 
PaO2 – arterial partial pressure of oxygen  
PaCO2  – arterial partial pressure of carbon dioxide 
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Table 2.2 – Initial Respiratory and hemodynamic characteristics of ventilated and 
non-ventilated animals 
 
 Non-ventilated 
(n=20) 
Ventilated   
(n=10) 
p value 
   Animal Weight 320gm (+/- 8) 336 gm (+/- 18) 0.37 
   Initial Respiratory Rate 56 bpm  (+/- 3) 63 bpm (+/- 4) 0.2 
   Initial Tidal Volume 2.84 cc (+/- .19) 2.38 cc (+/- .37) 0.25 
   Initial Blood Pressure (MAP)! 90 mmHg (+/- 3) 88 mmHg (+/- 3) 0.64 
   Initial Respiratory Effort*  -6.1 mmHg (+/- 2.2) -5.6 mmHg (+/- 1.3) 0.49 
   Initial Pulse Rate’ 354 bpm (+/- 10) 379 bpm (+/- 14) 0.19 
   Initial ET PCO2 49 mmHg (+/- 1.1) 53 mmHg (+/- 1.1) 0.02 
 
 
*Respiratory Effort is measured as peak inspiratory pressure 
! = Includes group III - paralyzed and ventilated animals (n=13) 
Values are reported as mean (+/- standard error) 
 
MAP = mean arterial pressure 
 
There was no statistical difference between ventilated and non-ventilated animals 
at baseline except for ET PCO2.  Paralyzed and ventilated animals (Group III, not 
included in the table except for MAP) showed a decrease in the pulse rate (378 
vs 322, p=0.01) but no change in MAP (88 vs 98.9, p=ns) during the baseline 
period when compared to the ventilated at apnea group. 
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Figure 2.1 – Sample tracing of OP poisoned rat 
 
A sample tracing of a single OP poisoned rat from group 1 shows apnea 
occurring at 6:45 with a long period of no respiratory effort.  OP injected at 
broken line.  A break in the time scale allows us to see the terminal gasping that 
occurs as blood pressure approached zero.  The positive deflections in the 
esophageal tracing represent retching. 
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Figure 2.2 - Blood pressure and respiratory rate in OP poisoned animals with and 
without mechanical ventilation. 
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Grouped data sets show respiratory rate and mean arterial pressure for animals 
with acute OP and no further intervention (Group I) and mean arterial pressure 
for animals with acute OP and mechanical ventilation initiated at the point of 
apnea (Group II).  Results are shown as mean value +/- standard error (n=10 all 
groups) with respiratory rate (triangle) represented on the right axis and mean 
arterial pressure (solid and hollow circle) on the left axis. The respiratory rate of 
Group II is not shown, as it was almost identical to the respiratory rate curve of 
Group I.  In all groups poisoning occurred at 1 minute.  
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Figure 2.3 – Survival histogram ventilated and non-ventilated animals 
 
Grouped data sets for animals with OP exposure but no intervention (Group I) 
and all animals with OP exposure but mechanical ventilation (Group II and III) are 
displayed as mortality rate over time.  Data are binned into 5-minute time blocks 
and presented as the percent of animals that survived to the end of the time 
block.  Group IV (unanaesthetized) data was not available secondary to lack of 
invasive cardiovascular monitoring. 
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Figure 2.4 - Alveolar-arterial gradient and VE/VI ratio in animals that lived and 
died despite mechanical ventilation (Groups II and III) 
 
Data for animals receiving mechanical ventilation (Groups II and III) are plotted 
with VE/VI ratio on the Y-axis and A-a gradient on the X-axis.  Individual animal 
data are represented as ovals (animals that lived to study endpoint) and 
diamonds (animals that did not live to study endpoint).  Group averages for 
animals that lived and died are presented at boxes with SEM as bars.  Changes 
in A-a gradient from baseline (-1.3 vs 62.0, P=0.0004) and changes in the VE/VI 
ratio (28 vs 66%, P=0.0014) were significantly worse in animals that died. Note, 
three animals from Group II and III without ABG measurements are not included 
in this graph (one died and two lived). 
 
Change in A-a gradient from baseline 
(mmHg)  
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Figure 2.5 A,B - Alveolar-arterial gradient in animals receiving mechanical 
ventilation. 
2.5A 
 
2.5B. 
 
A - A graphical depiction of alveolar-arterial gradient for each animal that was 
exposed to OP and received mechanical ventilation throughout the experiment 
(Group III) is plotted over time.  One of the animals in this group is not included 
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due to inability to obtain the necessary data points. Arterial blood gas 
measurements were obtained on a pre-determined schedule with a 
measurement every 3 minutes initially (8 times) and then every 6 minutes (7 
times).  The alveolar-arterial gradient is presented as change from baseline 
levels.  All animals were poisoned at zero minutes (black arrow).  Although the 
animals in this figure were paralyzed, the range of point of apnea in other groups 
is represented by a black bar under the X-axis.  Data points for animals that 
survived to the study endpoint are solid shapes with data points for animals that 
died indicated by open shapes. 
 
B - A graphical depiction of alveolar-arterial gradient for each animal that was 
exposed to OP and received mechanical ventilation at the point of apnea (Group 
II) is plotted for control period, at the point of apnea, and study endpoint.  Six of 
the animals that received rescue mechanical ventilation had arterial blood gas 
measurements at these time points. The final endpoint was obtained just prior to 
cardiovascular collapse.  A-a gradients are presented as change from baseline.  
Data points for animals that survived are represented as solid shapes and data 
points for animals that died are open shapes. 
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Chapter III - Respiratory failure induced by acute organophosphate poisoning in 
rats: effects of vagotomy. 
 
Previously published - Gaspari RJ. Paydarfar D.  Respiratory failure induced by 
acute organophosphate poisoning: Effects of Vagotomy.  J Nuerotox. 2009 30(2) 
p298-304. 
 
 
3.1 Abstract 
 
In the previous chapter we showed that acute OP poisoning causes respiratory 
failure through two mechanisms: central apnea and pulmonary dysfunction. The 
vagus nerve is involved in both the central control of respiratory rhythm as well 
as the control of pulmonary vasculature, airways and secretions.  We used a 
modification of the previous rat model of acute OP poisoning, with and without a 
surgical vagotomy to explore the role of the vagus in OP-induced respiratory 
failure. Dichlorvos (2,2-dichlorovinyl dimethyl phosphate) injection (100mg/kg 
subcutaneously, 3x LD50) resulted in progressive hypoventilation and apnea in 
all animals, irrespective of whether or not the vagi were intact. However, 
vagotomized animals exhibited a more rapidly progressive decline in ventilation 
and oxygenation. Artificial mechanical ventilation initiated at onset of apnea 
resulted in improvement in oxygenation and arterial pressure in poisoned animals 
with no difference between vagus intact or vagotomized animals. Our 
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observations suggest that vagal mechanisms have a beneficial effect during the 
poisoning process We speculate that vagally-mediated feedback signals from the 
lung to the brainstem serve as a modest protective mechanism against central 
respiratory depressive effects of the poison and that bulbar-generated efferent 
vagal signals do not cause sufficient pulmonary dysfunction to impair pulmonary 
gas exchange.  
 
3.2 INTRODUCTION 
 
In chapter 2 we describe respiratory failure following acute OP poisoning with an 
early central apnea followed by later pulmonary effects [186].  Experimental 
studies support the idea that OP-induced respiratory failure results from local 
effects of OPs acting on brainstem circuits underlying respiratory 
rhythmogenesis, and on lung tissues underlying pulmonary secretory, airway and 
vascular function.  Application of acetylcholine or OP compounds to brainstem 
sites in medullary slice preparations results in a disruption of respiratory 
associated rhythmic activities[50, 187, 188].  These studies involve OP 
application to the pre-Botzinger complex, thought to be important for respiratory 
rhythmogenesis [88], but without the intact neural circuitry of an in vivo 
preparation. Experiments in both in vitro[50, 173, 189-191] and in vivo[49, 80, 
192-195] preparations demonstrate respiratory effects secondary to cholinergic 
stimulation of diverse areas within the pons and medulla. The mechanism of later 
pulmonary effects from OP intoxication has been studied in isolated lung 
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preparations[52, 53, 196]. OPs exert their effects via inhibition of 
acetylcholinesterase and subsequent increase in acetylcholine levels.  The 
primary source for pulmonary acetylcholine is the vagus nerve[197-199] and 
although the vagal trunks are transected in isolated lung preparations the 
acetylcholine-laden nerve endings remain intact within pulmonary tissue. It is 
accepted that acetylcholine from vagal nerve synapses is required for the 
pulmonary effects[200] of OPs.   In vivo and in vitro studies support a local 
pulmonary effect of OP through pulmonary cholinergic receptors on pulmonary 
vasculature [74, 124, 201, 202], smooth muscle [203-205] and mucosal glands 
[205-207].   
 
Although the local effects of OPs on brainstem and lung are sufficient to explain 
the central apnea and the pulmonary dysfunction associated with acute 
intoxication, the role (if any) of neural signals between the brainstem and the lung 
is uncertain.  The vagus is the major neural pathway that interconnects the 
brainstem and the lung. The local effects of OPs could result in the stimulation of 
slowly adapting mechanoreceptors, rapidly adapting mechanoreceptors and C-
fiber receptors that feedback via the vagus to brainstem respiratory center [59, 
208, 209]. Conversely, OP-induced changes in the brainstem could result in 
pulmonary effects via vagal efferent projections. Vagal efferent fibers carry 
signals from bulbar circuits to bronchial smooth muscle [72], pulmonary secretory 
tissue [76] and pulmonary vasculature [210].  Cholinergic stimulation of the 
ventro-lateral surface of the medulla results in increased pulmonary 
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secretions[211] and the increase in pulmonary secretion from pulmonary irritants 
is decreased in vagotomized animals[212].  However, it remains unclear to what 
degree bulbar-generated efferent vagal activity contributes to pulmonary 
dysfunction during acute OP intoxication and if central effects of OPs mediated 
through vagal efferents predominate over local cholinergic effects at the 
pulmonary synapses. 
 
We have further developed the animal model of OP poisoning described in 
chapter 2 to test whether signals traveling via the vagus nerve play a role in the 
development of OP-induced respiratory failure.  First, we postulated that vagally 
mediated peripheral feedback influences OP-induced central apnea. Therefore 
we hypothesized that ablation of the vagus alters the natural history of OP-
induced apnea. In the present study our results appear to support this hypothesis 
because vagotomized animals suffer a more rapidly progressive hypoventilation 
and central apnea following OP exposure, compared to animals with intact vagi.  
 
Second, we postulated that vagally mediated efferent pathways from bulbar 
circuits to the lung are activated by OP-poisoning and therefore we hypothesized 
that ablation of the vagus reduces pulmonary dysfunction associated with OP 
exposure. In order to test this hypothesis, we resuscitated animals with central 
apnea induced by OP-poisoning, and we measured arterial blood oxygen levels 
during fixed mechanical ventilation. We found that during OP poisoning 
vagotomy was not associated with any improvement in arterial oxygen levels, 
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suggesting that pulmonary gas exchange during OP poisoning was not affected 
by the vagus.  
 
3.3 MATERIALS AND METHODS 
 
General Preparation 
The animal model used in this study is a further development of the animal model 
described in detail on page 24 in chapter 2.  
Experimental Groups 
Experimental groups are listed in Table 3.1 and consisted of animals with intact 
vagus nerves (n=30) and animals that were vagotomized (N=20).  There were 
two groups of animals with intact vagi, either spontaneously breathing throughout 
or animals that were spontaneously breathing prior to the poisoning but received 
mechanical ventilation at the point of apnea (see Figure 3.1 for schematic).  
There were also two similar groups of vagotomized animals, spontaneously 
breathing throughout and animals that received mechanical ventilation at the 
point of apnea.  All animals that did not receive mechanical ventilation 
spontaneously breathed 100% oxygen.  Animals with mechanical ventilation had 
ventilation initiated at the point of apnea.  These animals were spontaneously 
breathing up to the point of apnea but were mechanically ventilated once they 
stopped breathing.  In these experiments, mechanical ventilation was used as an 
experimental tool to allow more detailed pulmonary and cardiovascular 
recordings post apnea.  Initiating mechanical ventilation at the point of apnea 
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allowed us to remove the confounding effect of apnea so that we could study 
arterial oxygenation during constant ventilation.  This allowed measurements of 
pulmonary gas exchange during the later period of pulmonary dysfunction that 
otherwise would have been unobtainable.  Supplemental oxygen for animals in 
the group who received mechanical ventilation at the point of apnea was titrated 
to achieve an arterial PO2 between 100 and 110 mmHg during the baseline 
period (i.e., prior to injection of dichlorvos).  Once this was achieved, the FIO2 
was not changed throughout the experiment.  Arterial blood was collected via an 
arterial line by withdrawal of 0.2cc’s of blood and PO2, PCO2, and pH were 
measured (Rapidlab 248, Bayer Medical) during the baseline pre-poisoning 
period, around the time of apnea and during the post-apnea period for the 
mechanically ventilated animals only.  A-a gradient blood gas measurements are 
reported as a change from baseline. 
 
Surgical Vagotomy 
Mid-cervical vagotomy was performed via an anterior approach under general 
anesthesia.  The vagi were dissected away from the cervical sheath and 
complete transaction was confirmed by direct visualization. Anesthetic agents did 
not change between groups and all animals remained under general anesthesia 
for surgical procedures, baseline period and the experiment.  Vagotomy caused 
transient changes in blood pressure and breathing that stabilized after 10 
minutes. Therefore the vagus nerve was transected 20-30 minutes (range) prior 
to administration of dichlorvos.  Sham surgery was performed on all animals with 
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intact vagus nerves and consisted of the same neck dissection performed in the 
vagotomy surgery with the exception that the vagus nerve was not transected. 
The sham surgery was also followed by a 25-35 minute period before 
administration of dichlorvos. 
 
Data Analysis 
Data were continuously recorded and averaged into 15-second bins.  Changes in 
oxygen saturation, respiratory rate, volume of inspired gas, minute ventilation, 
pulse rate and mean arterial pressure over time were calculated. Statistical 
significance of changes over time was determined using a repeated measure 
ANOVA.  Mortality was analyzed using a chi-square test. Single comparisons of 
mean values between groups were analyzed using a Student’s t-Test. 
Differences were considered significant for p-values <0.05.Results are presented 
as mean (+/- standard error of the mean (SEM)) unless otherwise stated. 
 
3.4 RESULTS  
 
Baseline Measurements 
Baseline cardiovascular and respiratory values for all groups are listed in Table 
3.2.  Vagotomized animals (Group 1b & 2b) exhibited significantly lower baseline 
respiratory rate and minute ventilation, compared to the vagi intact animals 
(Group 1a & 2a). As expected, vagotomized animals demonstrated a larger 
volume of inspired gas. Vagotomized animals exhibited no significant change in 
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baseline blood pressure or pulse rate when compared to vagus intact animals, as 
reported previously in rats [213].  In summary, the baseline characteristics for 
each group are what would be expected from previous literature[214]. 
 
Group 1: Vagotomy was Associated with More Rapidly Progressive 
Hypoventilation and Circulatory Collapse (Figures 2-4) 
Following dichlorvos injection, all animals exhibited a rapid decline in respiratory 
rate, and minute ventilation (Figure 3.2a,b). However, hypoventilation was more 
rapidly progressive in vagotomized animals.  Figures 3.2a and 3.2b (from 
animals in Group 1a and 1b) show that the decline in respiratory rate and 
ventilation over the first 6 minutes following OP poisoning was more rapid in 
vagotomized animals compared to vagus intact animals (p=0.018 for respiratory 
rate, and p=0.023 for minute ventilation, repeated measure ANOVA). The 
beneficial effect of an intact vagus was modest. For example at 5 minutes, 
animals with intact vagi exhibited a 54% greater minute ventilation compared to 
vagotomized animals. Animals with intact vagi (Group 1a) developed central 
apnea an average of 5.47 min (+ 0.73 min) after sub-cutaneous injection of 
dichlorvos.  Vagotomized animals exhibited central apnea an average of 4.4 min 
(+ 0.55 min) after poisoning.  Therefore an intact vagus in rats poisoned with 
dichlorvos results in a significant reduction of the central hypoventilation 
associated with dichlorvos. The more severe hypoventilation preceding apnea 
seen in vagotomized animals corresponded to a trend toward more severe 
decrease in transcutaneous oxygen saturation compared to animals with intact 
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vagi (Figure 3.3, p=0.071, ANOVA) but the difference did not quite reach 
statistical significance. 
 
Initial respiratory failure was followed by cardiovascular collapse and death in 
both vagi intact and vagotomized animals (Groups 1a and 1b) that did not 
receive mechanical ventilation. Animals in both groups showed an initial episode 
of hypertension before a gradual decline in mean arterial blood pressure (MAP) 
but the decline differed between vagi intact and vagotomized animals (Figure 3.4, 
p=0.001 ANOVA).  The difference in MAP was greatest between groups at 10 
min post dichlorvos (9% vs 110% of baseline) but the MAP was almost the same 
(0 vs 9.9% of baseline) at 40 minutes.  Average time to 50% below baseline MAP 
was 6.83 min for vagotomized animals and 19.75 min for intact animals (students 
t-test, p=0.003). 
 
 
Group 2: Lack of Effect of Vagotomy on Pulmonary Oxygenation and Circulation 
During Fixed Mechanical Ventilation- 
Animals receiving mechanical ventilation at the point of apnea (Groups 2a and 
2b) showed distinct differences before and after the initiation of mechanical 
ventilation.   Figure 3.5 a-c shows the respiratory changes for animals that 
receive mechanical ventilation at the point of apnea. The data in these 
experiments confirmed the findings for the Group 1 experiments, i.e. that 
vagotomized animals have more profound hypoventilation than the vagi intact 
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animals.  Respiratory rate and minute ventilation declined more rapidly in 
vagotomized animals (p,0.001 and p=0.004 respectively, ANOVA) but there was 
no significant change in volume of inspired gas (p=0.10, ANOVA) (Fig 3.5a,b,c).  
Once the animals were placed on a mechanical ventilator there was no 
difference (3.5 a,b,c, p<0.05, ANOVA).  Similarly, the time to apnea between 
groups was not different (7:24 vs. 8:37, p=ns).  Arterial blood gas measurements 
in Group 2 animals at baseline, apnea and post apnea are given in Table 3.3.   At 
the point of apnea vagotomized animals (Group 2b) showed a significantly lower 
arterial PO2  (75.0 vs. 38.9 mmHg, p=0.004) and increase in PCO2 (45.1 vs. 63.0, 
p=0.045). The difference in arterial PO2 was not due solely to changes in 
ventilation because the A-a gradient at the point of apnea was worse in 
vagotomized animals (46.4  (+/- 7.0) vs. 68.8 (+/- 5.2), p=0.045) but no difference 
was seen between groups at baseline (5.06 (+/- 0.85) vs. 7.2 (+/- 0.9), p=0.10) or 
post apnea (16.3 (+/-15.0) vs. 7.0 (+/-9.6), p=ns) (Figure 3.6, Table 3.3) despite 
similar ventilation (pCO2 48.9 (+/- 5.04) vs. 44.7 (+/- 4.53).  Post apnea arterial 
blood gas samples were drawn at similar times from initiation of ventilation (10.42 
min vs. 11.13 min).  The range of oxygenation for vagus intact (31-194) and 
vagotomized animals (10-171) supports our previous findings of variability within 
the poisoning model[186] with some vagus intact animals catastrophically 
affected and others less so.  In summary, vagotomy resulted in an initial 
deterioration of pulmonary function but there was no difference in pulmonary 
function post apnea between vagotomy and vagus intact animals.  It is important 
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to note that these effects are distinct from the effects of vagotomy on OP-induced 
central apnea discussed previously. 
 
 
Mechanical ventilation at the point of apnea prevented a complete cardiovascular 
collapse in most animals but vagotomized animals remained close to 100% of 
baseline MAP while vagus intact animals declined below 70%. However these 
trends were not statistically significant (Figure 3.7a, p=ns, ANOVA). Vagotomized 
animals showed a pulse rate greater then 70% of baseline throughout the 
experiment while vagus intact animals declined below 50% but again without 
statistical significance (Figure 3.7b, p=ns, ANOVA). An analysis of the mortality 
rates between groups receiving mechanical ventilation showed no difference 
between groups (15% vs 20%, p=ns, Chi-square).  All of the animals that died 
despite mechanical ventilation showed tracheal secretions filling their tracheal 
tube at the time of death.  
 
3.5 DISCUSSION 
 
Our results suggest that vagal mechanisms have protective effects on respiratory 
function in a rat model of OP poisoning. In the early phase of poisoning, vagal 
mechanisms appear to blunt the progressive hypoventilation in spontaneously 
breathing animals. We infer this protective role of the vagus because 
vagotomized animals exhibit a more precipitous drop in ventilation, compared to 
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animals with intact vagi. However, despite vagal efferent connections to the 
glands and smooth muscle in the airways of the lung, when apneic animals are 
resuscitated by artificial ventilation, vagal mechanisms appear to have no effect 
on pulmonary gas exchange during poisoning, i.e. vagotomized, artificially 
ventilated animals have similar oxygenation compared to vagus intact animals.   
 
Previous studies have described a role of vagal afferents in altering central 
respiratory activity, see reference [209] for a comprehensive review. Rapidly 
adapting mechanoreceptors and other small fiber afferents are activated by 
pulmonary “irritants” (e.g., smoke, histamine, capsaicin) that augment central 
inspiratory drive [215].  We found that vagotomized animals exhibited more 
profound hypoventilation following exposure to dichlorvos. OP agents cause 
bronchorrhea and bronchoconstriction and these airway effects could stimulate 
rapidly adapting irritant afferents, which in turn would enhance central neural 
inspiratory activity. The time course of dichlorvos induced pulmonary dysfunction 
(onset within 2 minutes) [51] is sufficient to support this hypothesis.  Alternatively, 
the OP might act directly to activate irritant receptors. Further work is needed in 
reduced preparation using recordings of vagal afferents and phrenic nerve to 
distinguish these possibilities, or to suggest an alternative mechanism for vagal 
enhancement of respiratory rhythm during OP poisoning. 
 
The cardiovascular effects of OP poisoning include hypotension, hypertension 
and cardiac arrest [48, 179, 216] with variable effects on pulse rate[217] 
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preceding cardiac arrest.  Our previous work in the rodent animal model has 
shown that central apnea and pulmonary insufficiency are independent of the 
cardiovascular effects [186], notably the central apnea occurs early in the 
poisoning process, long before the development of systemic hypotension. It is 
not clear if the cardiovascular affects of OP poisoning are secondary to central or 
peripheral effects of the poisoning.  Previous studies have demonstrated central 
mechanisms for cardiovascular changes via the vagus nerve [218] while others 
describe a direct effect of OP on the heart [219]. Our findings suggest that the 
heightened cardiovascular vulnerability in vagotomized animals can be explained 
at least in part by hypoxic inhibition of cardiovascular function [220].  In our study, 
animals with no mechanical ventilation (group 1) show increased cardiovascular 
collapse in vagotomized animals, but this difference is not seen in animals 
receiving mechanical ventilation (group 2). In short, vagotomized animals 
demonstrated earlier apnea and subsequently decreased tissue oxygenation that 
may have contributed to greater cardiovascular depression. We noted that, as a 
group more rapidly declining blood pressure was preceded by a steeper decline 
in transcutaneous oxygen saturation. However, one of the vagotomized animals 
showed a decrease in blood pressure prior to the development of arterial 
desaturation.  Cardiovascular-depressant effects of OP have been described in 
the literature[217] but it is unclear to what degree a direct cardiac effect is 
responsible for the hypotension seen in our animal model. Further research is 
required to fully characterize the cardiac effects of acute dichlorvos poisoning. 
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Vagotomized animals showed an increased A-a gradient at the point of apnea, 
which cannot be explained by known vagal mechanisms.  Vagal control of the 
airways and pulmonary vasculature is well established.  Vagal stimulation has 
been shown to constrict pulmonary airways[221], and vagotomy abruptly dilates 
pulmonary airways [222].    In addition, stimulation of the vagus causes 
vasodilatation of the pulmonary vasculature [223].  Previously demonstrated 
pulmonary effects of acute OP poisoning suggest that ventilation-perfusion (V-Q) 
mismatch in poisoned animals is due at least in part to decreased ventilation 
from bronchoconstriction.  If this were the sole mechanism then vagotomy would 
result in an improvement of pulmonary gas exchange, which our findings do not 
support. In our study, vagotomy-induced pulmonary bronchodilation or 
vasoconstriction or both could contribute to an increased V-Q mismatch and 
explain why the A-a gradient widened in vagotomized animals at the point of 
apnea.  
 
Finally, we found in poisoned animals that vagotomy had no effect on pulmonary 
oxygenation during fixed mechanical ventilation.  This result was unexpected. 
Previous studies have proposed a role of the vagus in acute OP poisoning [37] 
and “chemical vagotomy” with atropine is the main therapy for acute OP 
poisoning.  One possible explanation for our findings involves the effects of vagal 
efferent signaling on pulmonary smooth muscle and glandular tissue. We noted 
an increased volume of expired gas at baseline in vagotomized animals receiving 
mechanical ventilation, which was expected. The associated increase in airway 
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caliber in vagotomized animals would be beneficial during OP-induced 
pulmonary airway constriction.  Vagal control of pulmonary secretions is well 
established and would suggest a decrease in pulmonary secretions in 
vagotomized animals [211].  Our hypothesis that vagotomy would improve 
pulmonary oxygenation is not supported by our experiments. Furthermore, in 
artificially ventilated rats we found no difference between vagotomized and vagi 
intact animals in the number of animals who died with secretions filling the 
tracheal tube. This was unexpected as surgical vagotomy has been shown to 
decrease pulmonary secretions [212].  Vagal efferent signaling is not the only 
possible mechanism of OP induced pulmonary secretions as sectioning the 
vagus nerve does not remove the acetylcholine laden nerve terminals in the lung 
and direct application of OP to an isolated lung results in bronchorrhea [52].   
However, we did not directly measure pulmonary secretions in this study 
therefore additional studies are required to quantify the pulmonary secretory 
changes attributable to OP effects on lung synapses versus cholinergic 
mechanisms resulting from bulbo-pulmonary vagal signaling mechanisms.  
 
Our study suffered from some additional limitations.  By cutting the vagi we 
simultaneously eliminated vagal efferent and afferent signaling.  This prevented 
us from independently examining the effects of vagal efferent or afferent 
signaling in isolation. In addition, because we did not record vagal fiber activity in 
our model of OP poisoning, we are unable to test directly the effect of OP on 
vagal signaling. The present experiments provide evidence for a role for the 
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vagus nerve in an OP poisoning model, but future investigation will be needed to 
test more directly the separate role of afferent and efferent pathways. 
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Table 3.1  - Experimental Intervention for vagus intact and vagotomy groups 
 
 Vagus  
Status 
N Mechanical Ventilation FiO2 
Group 1a Vagi Intact 20 None 100% O2 
Group 1b Vagotomy 10 None 100% O2 
Group 2a Vagi Intact 10 Initiated at onset of 
apnea 
Titrated to achieve 
normoxia  
Group 2b Vagotomy 10 Initiated at onset of 
apnea 
Titrated to achieve 
normoxia 
FiO2 = Fraction of inspired oxygen  
N= number of animals in group 
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Table 3.2  -Baseline physiologic values for vagus intact and vagotomy groups 
 
 MAP HR MV Vi RR 
Group 
1a 
92.2 (2.3) 365.6 (7.0) 130.0 (7.5) 2.29 (0.10) 56 (2.2) 
Group 
1b 
102.3 
(8.71) 
349.6 (7.66) 99.6 (9.57)* 3.0 (0.39)* 33.7 (3.0)* 
Group 
2a 
84.1 (3.15) 369 (15.6) 136.1 (12.5) 2.16 (0.14) 62.7 (3.15) 
Group 
2b 
93.3 (5.40) 349.2 (10.2) 104.0 (8.19)* 2.87(0.23)* 36.1 (1.14)* 
MAP = mean arterial pressure (mmHg) 
HR = heart rate (beats/min) 
MV = minute ventilation (cc’s/min) 
Vi = Volume of inspired gas (cc’s) 
RR = respiratory rate (breaths/min) 
• indicates statistical significance when compared between groups (p<0.05)  
 
 
Results presented as average (+ standard error of mean).  Baseline values 
represent point prior to poisoning but post surgical procedure. 
 
Group 1a – Vagus intact, Spontaneously breathing throughout (n=20) 
Group 1b – Vagotomy, Spontaneously breathing throughout (n=10) 
Group 2a – Vagus intact, Mechanically ventilated (n=10) 
Group 2b – Vagotomy, Mechanically ventilated (n=10) 
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Table 3.3 – Arterial blood gas measurements before and after exposure to 
dichlorvos 
 
            
 pH PaO2 PCO2 pH PaO2 PCO2 pH PaO2 PCO2 
Group 
2a 
7.30 
(0.01) 
115.5 
(1.53) 
44.2 
(2.46) 
7.23 
(0.01) 
75.0 
(8.54) 
45.1 
(3.61) 
7.18 
(0.03) 
104.9 
(16.4) 
48.9 
(5.04) 
Group 
2b 
7.25 
(0.02) 
115.9 
(2.82) 
41.3 
(3.78) 
7.18 
(0.03) 
38.9 
(3.84) 
63.0 
(8.75) 
7.21 
(0.02) 
117.0 
(14.8) 
44.7 
(4.53) 
 
Results presented as Average (SEM) 
 
Group 2a – Vagus intact, Mechanically ventilated (n=10) 
Group 2b – Vagotomy, Mechanically ventilated (n=10) 
Baseline At Apnea Post Apnea 
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Figure 3.1 - Schematic of experimental interventions for vagus intact and 
vagotomy groups.  
 
Dichlorvos (100mg/kg) was given at dotted line.  The only difference between 
study groups is the initiation of mechanical ventilation at the point of apnea in 
Group 2.   
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Figure 3.2 A,B  - Comparison of respiratory rate and minute ventilation between 
vagi intact and vagotomized animals (Group 1a and 1b) without mechanical 
ventilation.   
0 1 2 3 4 5 6
0
20
40
60
80
100 Vagi  Intact
Vagotomy
Time after injection of dichlorvos
(min)
 
 
Results are shown as a percentage of baseline +/- standard error.   There was no 
difference in time to apnea (p=ns, student’s t-test) between vagotomized (n=20) 
Figure 3.2 A 
Figure 3.2 B 
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and vagi intact animals (n=10).  Respiratory rate and minute ventilation were 
lower in vagotomized animals (p<0.05, ANOVA).  For example, at 4 minutes 
respiratory rate (23 vs 52% of baseline) and minute ventilation (14 vs 52% of 
baseline) was less in vagotomized animals. 
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Figure 3.3 –  Evolution of hypoxia after onset of apnea in vagi intact and 
vagotomized animals (Group 1a and 1b) without mechanical ventilation.   
0 1 2 3 4 5
0
25
50
75
100
Vagotomy
Vagi Intact
Time after onset of apnea
(min)
 
Oxygen saturation after the point of apnea was lower in vagotomized animals but 
it did not reach statistical significance (p=0.071, ANOVA).  The greatest 
difference in oxygen saturation between groups was at 4 minutes (20 vs 74%, 
p=ns). Results are shown as mean values +/- standard error (n=5 each group).   
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Figure 3.4 – Changes in blood pressure of vagi intact and vagotomized animals 
without mechanical ventilation.  
 
 
 
Grouped data sets show mean arterial pressure for animals following dichlorvos  
(Groups 1a and 1b).  Vagotomized animals showed a significantly lower blood 
pressure following dichlorvos (p<0.05, repeated student’s t-test after 5 minutes 
post poisoning.  Data are shown from point of dichlorvos injection (time 0).  
Results are shown as percent of baseline mean arterial pressure +/- standard 
error (n=20 Group 1a, n=10 Group 1b)).   
Figure 3.4 
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Figure 3.5 A,B, and C 
 
Comparison of respiratory rate, volume of expired gas, and minute ventilation 
between vagi intact and vagotomized animals that received mechanical 
ventilation at the point of apnea (Group 2a and 2b).   
 
 
 
Figure 3.5A 
Figure 3.5b 
Figure 3.5B 
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Results are shown as raw data synchronized at the point of apnea (black arrow).  
Animals are spontaneously breathing to the left of the arrow and mechanically 
ventilated to the right of the arrow. Prior to apnea respiratory rate was lower in 
vagotomized animals (p<0.001, ANOVA) but volume of expired gas was 
unchanged (p=0.10, ANOVA) resulting in a decrease in minute ventilation 
(p=0.004, ANOVA).  Following apnea, there was no difference between 
vagotomized and vagus intact animals (p=ns, ANOVA).  The greatest difference 
between groups for respiratory rate (66.5 (+20.4) vs 81.9 (+11.9) bpm), volume 
of expired gas (1.48 (+0.53)) vs 1.97 (+0.56) cc) and MV (98.3 (+10.9) vs 147.9 
(+76.0) cc/min) post apnea was at 1 min. 
 
Figure 3.5C 
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Figure 3.6 – Oxygen saturation around the point of apnea in vagus intact and 
vagotomized animals.   
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Grouped data sets show oxygen saturation for animals with dichlorvos and 
mechanical ventilation initiated at the point of apnea  (Groups 2a and 2b). 
Oxygen saturation in vagotomized animals (n=10) was lower prior to the point of 
apnea (p=0.003, ANOVA) but there was no difference after the point of apnea 
(p=ns, ANOVA) when compare to vagus intact animals (n=10).  At 5 min post 
apnea oxygen saturation was almost the same in both groups (74.5 (+40.5) vs 
78.7 (+31.3)).  Data are shown referenced to the point of apnea (indicated by 
black arrow).   Results are shown as mean values +/- standard error (n=9 both 
groups).  
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Figure 3.7A, B –  Changes in blood pressure and pulse rate of vagi intact and 
vagotomized animals with mechanical ventilation at apnea. (Groups 2a and 2b).  
 
Dichlorvos was injected at time zero.  Vagi intact animals showed a greater drop 
in blood pressure after the initiation of mechanical ventilation but the difference 
was not statistically significant (p=ns, ANOVA).  MAP at 25 min was 62% (+43) of 
Figure 3.7A 
Figure 3.7B 
n=10 both groups 
n=10 both groups 
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baseline in vagi intact animals vs 98% (+26) in vagotomized animals.  Vagi intact 
animals showed a greater drop in pulse rate after the initiation of mechanical 
ventilation (p=ns, ANOVA).  Pulse rate at 25 min was 47% (+32) of baseline in 
vagi intact animals vs 72% (+16) in vagotomized animals.  Results are shown as 
a percentage of baseline mean arterial pressure +/- standard error or baseline 
pulse rate +/- standard error (n=10 both groups).  
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Chapter 4 - Pulmonary changes in gas exchange following antimuscarinic 
therapy 
  
4.1 Abstract 
 
Atropine, an anti-muscarinic drug, is the primary therapy for acute OP poisoning.  
Cholinergic nerves that innervate pulmonary smooth muscle, glands and 
vasculature are active in regulating pulmonary gas exchange.  It is unclear if 
atropine induces a ventilation-perfusion mismatch by altering cholinergic tone at 
matched airways and vasculature in the lung.  We hypothesized that atropine 
causes alterations in pulmonary gas exchange.  We conducted a prospective 
interventional study with detailed physiologic recordings in anesthetized, 
spontaneously breathing rats (n=8).  Animals breathing a normoxic gas mixture 
were titrated to a partial arterial pressure of oxygen (PaO2) of 110-120.  An 
escalating dose of intravenous (IV) atropine (0.001, 0.01, 0.1, 5 and 20 mg/kg) 
was administered.  Arterial blood gas measurements were recorded every 2 
minutes (x5) at baseline and following each of the five doses of atropine.  
Between-group comparisons were made with Student t-tests.   
      Oxygenation decreased immediately following IV atropine despite a small 
increase in volume of inspired air and no change in respiratory rate and 
respiratory effort. Oxygen saturation decreased with increasing dose of atropine.  
Arterial blood gas analysis showed an increase in pulmonary dysfunction 
characterized by a widening of the A-a gradient (p<0.003 all groups except 
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lowest dose of atropine).  The change in A-a gradient from baseline was 0.7, 
21.4, 29.7, 30.2 and 30.3 at 0.001, 0.01, 0.1, 5 and 20 mg/kg respectively.   
Mean arterial pressure and pulse rate showed no changes with the lower doses 
of atropine but mean arterial pressure decreased significantly with the highest 
two doses.  In conclusion, atropine decreases pulmonary gas exchange in this 
rat model, using doses that are comparable to the human therapeutic range.   
 
4.2 Introduction 
 
OP compounds have been used commercially for over 50 years yet there has 
been no significant advancement in the treatment of OP toxicity since the 1960’s.  
The primary therapy for acute OP poisoning is atropine, an anti-cholinergic agent 
with central and peripheral actions.  Atropine has a long clinical history but 
research into the pulmonary effects of atropine is incomplete. Atropine is rarely 
considered to have significant effects in the lung other then effects on pulmonary 
glandular tissue [162] and airway smooth muscle [43, 114, 224].  
 
Acute OP toxicity results in profound changes in pulmonary physiology and 
severe poisonings clinically present with a difficulty maintaining adequate 
oxygenation and ventilation[7, 28].  Standard of care for OP toxicity includes 
treatment with atropine, sometimes in massive doses.  Severe OP poisoning 
commonly results in the need for mechanical ventilation in addition to anti-
cholinergic therapy.  Hypoxia in mechanically ventilated, OP-poisoned patients is 
 79 
multi-factorial involving bronchoconstriction, pulmonary secretions and/or 
pulmonary edema but the exact physiologic mechanism of the hypoxia is 
unknown.   
 
Effective gas exchange in the lung is accomplished through matching ventilation 
and perfusion but the regulatory mechanisms that match ventilation and 
perfusion are not well understood. Cholinergic nerves that innervate pulmonary 
smooth muscle, glands and vasculature are active in regulating pulmonary gas 
exchange.  Atropine has known effects on both the airways and pulmonary 
vasculature and it is unclear if these effects disrupt an existing regulatory process 
required for efficient exchange of gas from the airways to the vasculature.  A 
single study on the pulmonary effects of atropine in humans found an impairment 
of gas exchange[35] but this effect was not completely characterized.  Previous 
studies have shown that atropine dilates pulmonary arteries[225] and bronchial 
airways[224] but less attention has been paid to the effect on gas exchange.  
Dilatation of pulmonary arteries provides more blood to a region of the lung, 
resulting in a vascular shunt and a ventilation-perfusion mismatch if there is no 
matched increase in airflow.  We hypothesize that intravenous atropine results in 
a ventilation-perfusion mismatch in a dose dependant manner. 
 
4.3 Materials and Methods 
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The University of Massachusetts institutional animal use and care committee 
approved all procedures and protocols used in these experiments.   The animal 
model used in this series of experiments was an adaptation of the one without 
mechanical ventilation described in chapter 2.  However, in these experiments 
the amount of inspired oxygen (FiO2) was titrated prior to initiating the 
experiment to a partial arterial pressure (PaO2) of 110-120 mmHg.  Eight adult 
male Wistar rats (300 gms) were anesthetized using isoflurane (Abbott Labs, 
North Chicago, IL) prior to tracheostomy and placement of arterial catheters.  
The animals spontaneously breathed a constant mixture of oxygen and 
anesthetic throughout the course of the experiment.  Physiologic recordings were 
the same as those described in chapter 2 using an identical data acquisition 
system.  
 
Baseline respiratory and cardiovascular parameters were recorded for at least 20 
minutes prior to each animal receiving escalating doses of atropine at 0.001, 
0.01, 0.1, 5 and 20 mg/kg intravenously in a volume of 0.2 ml of normal saline. 
Injections of 0.2 ml of normal saline (vehicle only) were performed between the 
highest two doses of atropine.   An additional group of animals (n=3) received 
escalating doses of glycopyrrolate (peripheral anti-muscarinic) at 0.006, 0.06 and 
0.6 mg/kg intravenously in a volume of 0.25m of normal saline. Sequential 
arterial blood gas analyses (Rapidlab 248, Bayer Healthcare East Walpole MA) 
were performed every 2 minutes (5 times) following the injection of each atropine 
or glycopyrollate dose.  Volume of blood withdrawn for each blood gas analysis 
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was between 0.1 and 0.25 ml. The animal’s respiratory and cardiovascular 
recordings were allowed to return to baseline values prior the next dose of 
atropine.  
 
Statistical analysis of data was performed using a student’s t-test or ANOVA 
where appropriate.  Data is presented as mean + standard deviation unless 
otherwise indicated.  P values less then 0.05 are considered significant and p 
values less then 0.1 are indicated by p=ns. 
 
4.4 Results 
 
Escalating doses of atropine produced pulmonary effects in a dose-dependent 
manner.  Minute ventilation (MV) increased at all doses except for the smallest 
(no effect) and largest (decreased MV) doses of atropine (p<0.001).  This 
increase in MV was primarily related to an increase in the volume of inspired gas 
and not the respiratory rate (figure 4.1a-c).  There was no statistical change in 
respiratory effort at any of the doses of atropine as measured by changes in 
esophageal pressure (figure 4.2, p=ns).  Pulmonary gas exchange decreased as 
atropine dose increased with A-a gradient widening at all atropine doses greater 
then 0.001 mg/kg (figure 4.3, p<0.0001)).  Oxygen saturation decreased over this 
same dose range (figure 4.4, p<0.0005)).  Similar effects were seen after 
injection of glycopyrrolate with a peak A-a gradient of 21, 22, and 47 for 
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escalating doses of the drug.  Injection of vehicle alone had no effect on oxygen 
saturation or arterial blood gas analysis. 
 
The pulmonary effects of atropine peaked early after the dose was administered 
and diminished quickly.  In all groups except the highest dose of atropine the 
oxygen saturation fell immediately after the atropine was administered but began 
improving within six minutes of atropine injection. (figure 4.5, p<0.0001 all 
groups)  In the dose range that affects cardiac parameters in humans, the 
oxygen saturation reached baseline levels within 10 minutes of atropine injection.  
(figure 4.5b) 
 
Some of the cardiovascular effects of atropine also showed a dose response.  
Blood pressure declined with escalating doses of atropine (figure 4.6, p<0.0001)) 
but pulse rate remained unchanged in all groups.   These effects have been 
previously described in rats[226].  Not all animals survived the highest dose of 
atropine with 3 of the 8 animals showing cessation of cardiac activity soon after 
injection of the atropine.   
 
4.5 Discussion 
 
Atropine induced a dose dependant pulmonary dysfunction in spontaneously 
breathing, anesthetized rats with decreased gas exchange as evidenced by 
systemic hypoxia despite an increase in minute ventilation. This effect of atropine 
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is most likely secondary to anti-muscarinic effects as glycopyrrolate 
demonstrated a similar effect.  The decrease in oxygen saturation is 
counterintuitive as atropine causes an increase in pulmonary ventilation and 
FiO2 does not change.  There are two possible mechanisms to account for our 
findings; either there was a decrease in the ability of oxygen to diffuse across the 
alveolar-arteriole interface or pulmonary vascular changes resulted in vascular 
shunting.  It is more likely that the findings are due to vascular dilatation as 
atropine is a vasodilator of the peripheral vasculature[227] and pulmonary 
arterials[225].   
 
Atropine has well documented effects on bronchial smooth muscle tone with 
bronchodilation[224] lasting for hours following intravenous administration (half 
life 1-2 hours)[228].  To reconcile this fact with our finding that atropine 
decreases oxygenation requires either 1) segmental effects allowing decreased 
ventilation to areas of the lung with increased perfusion or 2) temporal effects 
with increased perfusion occurring prior to increased ventilation.  Segmental 
pulmonary airway constriction (or lack of dilatation) is possible but unlikely as 
atropine induces an aggregate increase in airflow.  The time course of the 
bronchodilatory effects of atropine supports a window of time when increased 
pulmonary blood flow is not matched by increased pulmonary airflow.  This 
cascade of events would also explain the transient nature of the hypoxic effects 
of atropine if early vascular dilatation is followed closely by pulmonary airway 
dilatation.  
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The autonomic control of pulmonary vasculature has not been well characterized 
and it is not clear if the effects of atropine we describe are mediated centrally or 
peripherally. Studies in the 1980’s demonstrated that vagal stimulation resulted in 
vasodilatation of bronchial arteries [74].  Studies in an isolated lung preparation 
have demonstrated peripherally mediated effects with vasodilatation from the 
direct application of atropine[225].  In both cases pulmonary artery dilatation 
occurred within 10 seconds of the stimulus (application of atropine or stimulation 
of the distal vagal trunk), consistent with the time course of the changes seen in 
our experiments[223].  To make things more complicated, it may be that 
autonomic control is not the sole physiologic mechanism for changing pulmonary 
vascular tone as increases in tracheobronchial blood flow during cold air 
hyperventilation are unaffected by either vagotomy or beta-blockade[229].  
 
Results similar to ours have been described in one previously published human 
study. Healthy subjects exposed to a single dose of atropine (0.02 mg/kg) under 
mildly hypoxic conditions showed a small decrease in oxygenation despite no 
change in ventilation[35].  This study advances those findings by demonstrating 
that the hypoxia follows a dose-response relationship and is seen in normoxic 
conditions.   We also were able to demonstrate that there was no clinical effect in 
airway resistance as respiratory effort and pleural pressure remained unchanged 
during the experiment. 
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It is unlikely that the cardiovascular effects of atropine contributed significantly to 
changes in pulmonary oxygen exchange.  Blood pressure decreased between 
10-75% with increasing levels of intravenous atropine however multiple lines of 
evidence support our contention that the hypotension was not the reason for the 
hypoxia.  First we noted increasing hypotension over the first two minutes for the 
three highest doses of atropine but there was no corresponding decrease in 
oxygen saturation over the same time period.  Second, in the two highest doses 
of atropine oxygen saturation failed to improve over time despite improving mean 
arterial pressure.  Finally, a study looking at physiologic changes during 
hypotension and blood loss in rats showed the reverse of our findings, an 
increase in arterial oxygenation and a decrease in the alveolar-arteriole 
gradient[230]. 
 
Conclusion 
The administration of intravenous atropine produces pulmonary effects in a dose 
dependent fashion with increasing doses of atropine resulting in greater levels of 
hypoxia due to increasing V-Q mismatch.  We hypothesize that these effects are 
related to the effects of atropine on the pulmonary vasculature. 
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Figure 4.1 A,B,C  - Respiratory rate, volume of inspired gas and minute 
ventilation following intravenous atropine 
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Grouped data sets (n=8) show respiratory rate, volume of inspired gas and 
minute ventilation from animals exposed to intravenous atropine in doses ranging 
from 0.001 to 20 mg/kg.  There was no difference in respiratory rates between 
groups (p=ns).  Volume of inspired gas was increased at 0.01 and 0.1 mg/kg and 
decreased at the highest dose (p<0.01). Minute ventilation increased at 0.01 
(134.5 + 19.5 cc/min), 0.1 (135.5 + 19.7 cc/min) and 5 mg/kg (132.6 + 19.1 
cc/min) over baseline (120.4 + 9.25  cc/min) but decreased at the highest dose 
(101.43 + 15.8, p<0.001). Results are shown as mean +/- standard deviation. 
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Figure 4.2 – Respiratory effort following intravenous atropine 
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Grouped data sets (n=8) show esophageal pressure from animals exposed to 
intravenous atropine.  Data consists of esophageal pressure over a dose range 
of atropine from 0.001 to 20 mg/kg.  There was no change in respiratory effort 
across groups (p=ns).  None of the esophageal pressure values (range 1.83-2.09 
mmHg) differed statistically from baseline (1.83 + 0.93 mmHg) except for the 
highest dose (1.5 + 0.75 mmHg). Results are shown as mean +/- standard 
deviation. 
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Figure 4.3 – Alveolar-arteriole gradient following intravenous atropine 
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Grouped data sets show calculated A-a gradients from animals exposed to 
intravenous atropine.   Data consists of arterial blood gas measurements 
performed immediately following intravenous atropine in doses ranging from 
0.001 to 20 mg/kg.  A-a gradients increased for all doses greater then 0.001 
mg/kg  (p<0.0001).  A-a gradients were essentially unchanged at 0.1 mg/kg and 
greater  (29.7, 30.1, 30.2 mmHg respectively). Results are shown as mean +/- 
standard deviation. 
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Figure 4.4 – Oxygen saturation two minutes following intravenous atropine 
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Grouped data sets (n=8) show oxygen saturation from animals exposed to 
intravenous atropine in doses ranging from 0.001 to 20 mg/kg.  Oxygen 
saturation measurements performed 1 minute following intravenous atropine.  
Oxygen saturation decreased in all study groups except for the smallest dose 
(p<0.0005).  As dose increased the oxygen saturation decreased from 96.7% 
(+1.4) to 81.7% (+13.9). Results are shown as mean +/- standard deviation. 
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Fig 4.5A – Oxygen saturation following intravenous atropine 
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Grouped data sets show oxygen saturation from animals exposed to intravenous 
atropine in doses ranging from 0.001 to 20 mg/kg.  Figure 4.5 includes all 
atropine doses and Figure 4.6 includes only atropine doses 0.001, 0.01 and 0.1 
mg/kg.  Increasing levels of atropine resulted in decreasing oxygen saturation 
(p<0.0001).  Oxygen saturation decreased immediately after intravenous atropine 
but recovered within 10 minutes for all groups except the two largest doses.  
Data are shown from point of atropine injection (time 0).  Results are shown as 
percent of baseline oxygen saturation. 
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Fig 4.5B – Oxygen saturation following clinically relevant doses of intravenous 
atropine that affect human cardiac function 
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Grouped data sets show oxygen saturation from animals exposed to intravenous 
atropine in doses ranging from 0.001 to 0.1 mg/kg.  Figure 4.5 includes all 
atropine doses and Figure 4.6 includes only atropine doses 0.001, 0.01 and 0.1 
mg/kg.  Increasing levels of atropine resulted in decreasing oxygen saturation 
(p<0.0001).  Oxygen saturation decreased immediately after intravenous atropine 
but recovered within 10 minutes for all groups except the two largest doses.   
Maximal effect was seen at 2 min for all doses (92.9 (+6.5), 89.9 (+3.9), and 85.6 
(+7.5) respectively).  Data are shown from point of atropine injection (time 0).  
Results are shown as percent of baseline oxygen saturation +/- standard 
deviation. 
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Fig 4.6 A,B– Blood pressure following intravenous atropine 
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Grouped data sets (n=8) show mean arterial pressure from animals exposed to 
intravenous atropine in doses ranging from 0.001 to 20 mg/kg.  Increasing levels 
of atropine resulted in decreasing mean arterial pressure (p<0.0001) that partially 
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recovered over the next 10 minutes. Data are shown from point of atropine 
injection (time 0).  Maximal effect was seen at 2 minutes for all atropine doses  
(93.7, 87.5, 70.8, 45.2, 25.8 respectively).  Figure 4.6b shows mean arterial 
pressure at 2 minutes.  Results are shown as percent of baseline mean arterial 
pressure +/- standard deviation for both graphs. 
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 Chapter V – Organophosphate-induced autoresuscitative breathing: The 
emergence of corrupted respiratory oscillator.   
 
5.1 Abstract  
 
It was noted anecdotally in earlier experiments that OP-induced apnea was not 
absolute.  Animals regain respiratory activity over time if they survive.  Here we 
show in a rat model of OP that breathing can resume spontaneously following 
prolonged central apnea. This autoresuscitative respiratory activity is suppressed 
by hypoxia, in contrast to the promoting effect of hypoxia on gasping. Analysis of 
phrenic nerve discharge activity reveals that peak inspiratory and post-inspiratory 
discharge activities are significantly reduced compared to eupneic breaths. In this 
animal model of OP, a form of autoresuscitative breathing emerges following 
prolonged central apnea that is physiologically distinct from both eupnea and 
gasping respiration.  
 
5.2 Introduction 
 
Acute OP causes progressive respiratory failure but we descried in chapter 2 that 
death could be prevented by artificial mechanical ventilation.  We noticed that in 
some animals, respiratory rhythm spontaneously resumed following prolonged 
central apnea, suggesting a form of autoresuscitative breathing.   
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The return of autoresuscitative breathing in our animal model may represent a 
resumption of normal eupneic respiration or the emergence of a gasping 
respiration.  Normal eupneic activity could return once the acetylcholinesterase 
inhibition by dichlorvos wanes.  Alternatively, as hypoxia progresses to anoxia, 
breathing activity can resume in the form of gasping induced by anoxic excitation 
of brainstem circuits [231, 232].  This inspiratory excitatory effect of severe 
oxygen deprivation is a component of a neural ‘autoresuscitative’ response that 
has been shown to improve tissue oxygenation during cardiac arrest [233, 234], 
and may be an important survival mechanism in infants that are prone to life 
threatening cardiopulmonary disturbances during sleep[231].   
 
Eupnea and gasping can be differentiated using the different characteristics of 
each respiratory activity.  Eupnea is supported by oxygenation and gasping is 
supported by anoxia.  In addition, eupneic breathing and gasping have different 
neural output patterns [235]. Phrenic inspiratory activity associated with gasping 
has a greater rate of rise, a higher peak level, and a longer inter-breath interval 
compared to the phrenic activity associated with eupneic breathing. The central 
neural circuits that generate these two distinct respiratory patterns may be 
anatomically distinct [236, 237], or may consist of a single or two overlapping 
circuits that are capable of switching functional states depending on the level of 
interstitial oxygen [238-240]. 
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In the present study, we analyze OP associated autoresuscitative breathing by 
characterizing its response to oxygen levels and by comparing its phrenic nerve 
activity to that of eupneic breaths.  We find that autoresuscitative respiratory 
activity is suppressed by hypoxia and is associated with a loss of the normal 
post-inspiratory discharge activity that is characteristic of eupneic breaths. Our 
findings suggest that in this animal model of OP, a form of autoresuscitative 
breathing emerges following prolonged central apnea that is physiologically 
distinct from both eupnea and gasping respiration. 
 
5.3 MATERIALS AND METHODS 
 
The University of Massachusetts Medical School Institutional Animal Care and 
Utilization Committee approved all experimental procedures and protocols.   
 
General Preparation 
The animal model and basic experimental methodology used in this study was 
described in chapter 2.  Figure 5.1 is an example of some of the recordings. 
Inspiratory effort of the animal was monitored during mechanical ventilation 
through an analysis of the esophageal pressure.  Inspiratory activity was 
visualized during positive pressure ventilation as negative deflections of the 
tracing (Figure 5.1).  To confirm oxygenation levels, arterial blood gas analyses 
were performed on select animals during times of steady state (baseline and 
during mechanical ventilation). 
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Phrenic Nerve Isolation and Recording 
The right phrenic nerve was isolated at the mid-cervical level using a dorsal 
approach.  An incision was made dorso-lateral to the spine in the cervical region 
and the scapula was retracted laterally.  The upper extremity on that side was 
retracted inferior-laterally and the muscles were bluntly dissected until the 
cervical nerve rootlets were identified exiting the paraspinal muscles.  The 
phrenic nerve was identified branching from the superior cervical rootlets, diving 
ventral to the cervical rootlets and traveling parallel to the spine caudally.  
Recordings were performed on an uncut phrenic nerve draped over a bipolar 
electrode and covered with petroleum jelly.  The signal was amplified (Molecular 
Devices, Sunnyvale, CA), filtered (lowpass and highpass cutoff 2000 Hz and 400 
Hz respectively) and conditioned using a noise reduction device (HumBug noise 
eliminator, Quest Scientific, Vancouver Canada).  Phrenic nerve activity was 
whole wave rectified and step-wise integrated over 50 ms intervals. The onset of 
the inspiratory phase of activity was defined when the integrated signal exceeded 
3 standard deviations above the mean of the signal during the mid- to late-
expiratory phase. In order to quantify the statistical properties of phrenic nerve 
activity for a full respiratory cycle during baseline and experimental conditions, 
we averaged integrated phrenic nerve activity with respect to time of inspiratory 
onset, i.e., event-triggered averaging.  
 
Experimental Groups and Protocols 
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Following all surgical procedures, a baseline period of at least 20 minutes was 
recorded before the animals received Dichlorvos (Sigma-Aldrich, St Louis MO) 
100mg/kg subcutaneously.  Recordings were continued until blood pressure and 
pulse rate declined to the study endpoint (death or 1 hour, whichever came first).  
Animals were grouped into two cohorts that differed in terms of oxygenation. 
Animals in Group I (transient hypoxia post apnea) received oxygen 
supplementation that was titrated to achieve a PaO2 of ~110 mmHg during the 
baseline (pre-poisoning) period; once this level was achieved the fraction of 
inspired oxygen (FiO2) was kept at the same level throughout the experiment.  
Animals in Group II (no hypoxia) received 100% inspired oxygen throughout the 
experiment. Both groups received mechanical ventilation initiated at the point of 
apnea that continued until the study endpoint (death or 1 hour, whichever came 
first).  Arterial blood was sampled for determination of PaO2 during the baseline 
period.  Apnea was defined as no respiratory effort or airflow for 20 seconds.   
 
Data Recording and Analyses 
Data were recorded as described previously.  Between-group comparisons were 
performed using an unpaired Student’s t-test, repeated measure ANOVA or 
Fisher’s Exact test where appropriate [176].  
 
5.4 RESULTS 
 
Autoresuscitative Breathing Following Organophosphate Poisoning 
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Animals in both groups demonstrated a central apnea with declining airflow and 
respiratory effort prior to the point of apnea (see table 5.1 for baseline 
characteristics). Apnea occurred an average of 4.53 min (+1.95) after poisoning, 
with no differences between groups (table 5.1, p=0.089).  The majority of animals 
with mechanical ventilation at the point of apnea survived to the end of the study.  
Some animals did not survive (5 of 17) despite mechanical ventilation with no 
differences between groups (2 of 7 in Group I vs 3 of 10 in Group II, p=ns).  
Animals that did not survive despite mechanical ventilation had a large amount of 
secretions filling the tracheal tube and an inability to ventilate.  
 
The different FiO2 between groups resulted in a difference in tissue oxygenation 
at baseline, at the point of apnea and post-poisoning (on ventilator), but a clinical 
difference in oxygen saturation between groups only occurred at the point of 
apnea (table 5.2).  Animals receiving a normoxic gas mixture (Group I) 
demonstrated no hypoxia for the first five minutes but dropped their oxygen 
saturation to 24% by 10 minutes post poisoning before rebounding to close to 
100% (fig 5.2a).  Animals inspiring 100% oxygen (Group II) showed virtually no 
change in oxygen saturation despite the decreasing respiratory rate (fig 5.2b).  
Arterial blood gas analysis during steady state periods (baseline, during 
mechanical ventilation) confirmed the oxygen saturation data.  The decreasing 
respiratory rate was unrelated to level of tissue oxygenation as respiratory rate 
decreased in both groups despite differing oxygenation levels (Figure 5.3).   
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There was a significant difference between the two groups in autoresuscitative 
breathing (Figure 5.4). No animals that survived to mechanical ventilation in 
Group I exhibited autoresuscitative breathing (0 of 7) whereas 4 out of 5 animals 
in Group II exhibited resumption of sustained (greater then 3 min) respiratory 
activity. The autoresuscitative breathing in these animals was characterized by 
an irregular, slow respiratory rate (8.6 bpm (4.2) lasting an average of 25.4 min 
(21.7).  Respiratory effort during autoresuscitative breathing decreased 52% 
(40.6) from baseline.  The difference in autoresuscitative breathing was not 
related to differences in MAP as the drop in blood pressure 30 minutes post 
dichlorvos did not differ significantly between groups (50% vs 56%, p= ns). 
 
Characterization of Phrenic Nerve Activity 
In order to characterize the neural inspiratory activities during autoresuscitative 
breathing following OP poisoning, we analyzed phrenic nerve activity in one of 
the animals receiving 100% oxygen.  Figure 5.5 shows the event-triggered 
average of integrated phrenic nerve activity for 100 consecutive breaths recorded 
during the baseline period and for 100 consecutive autoresuscitative breaths that 
resumed 19.7 min after onset of apnea.  Compared to the baseline breaths peak 
phrenic amplitude of autoresuscitative breaths decreased by 60%. Normalizing 
the peak amplitude allows a comparison of the morphology of integrated phrenic 
activity. There was no difference in the normalized phrenic activity during the 
inspiratory period. However, compared to the baseline phrenic activity, the 
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autoresuscitative breaths had reduced phrenic activity during the post-inspiratory 
period (repeated measure ANOVA , p<0.004).  
 
5.5 DISCUSSION 
Animals exposed to subcutaneous dichlorvos (100mg/kg) exhibit a rapidly 
progressive decline in respiratory activity culminating in apnea within minutes of 
exposure.  OP-induced central apnea is not absolute as autoresuscitative 
breathing post apnea was seen in some animals oxygenated with mechanical 
ventilation, but only in animals that were not hypoxic at the point of apnea.  
Phrenic activity during the autoresuscitative breathing was distinct from both 
eupnea and gasping.  Unlike eupneic respiration, phrenic peak inspiratory activity 
had a significantly longer inter-breath interval.  Unlike gasping respiration, the 
peak inspiratory activity was significantly decreased from baseline.  The phrenic 
neurogram had characteristics of eupneic breathing but without the normal post-
inspiratory inspiratory activity and did not demonstrate the characteristics of 
gasping respiration.  
 
The most important difference between groups is hypoxia at the point of apnea in 
Group I compared to the lack of any hypoxia in Group II.  The episode of severe 
hypoxia in Group I resulted in post-hypoxic respiratory depression demonstrated 
by a loss of autoresuscitative breathing.  It is well known that profound hypoxia 
causes respiratory depression in animals without intact carotid body afferent 
signaling[241].  Animals in this study had an intact glossopharyngeal nerve but 
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the OP poisoning may interfere with afferent signaling from the carotid body.  
Existing pontine neural mechanisms involved in post-hypoxic respiratory 
depression may be involved[242] but further study is needed.  Severe hypoxia at 
the point of apnea in Group I may have also contributed to the acute loss of 
respiratory activity but the respiratory depressant effects of severe hypoxia are 
eliminated with increased oxygenation.  Severe hypoxia cycled with oxygenation 
is a laboratory technique to reversibly suppress eupnea and elicit gasping[243].  
The increased FiO2 (100% O2) in Group II produced greater oxygen reserves that 
prevented hypoxia during apnea.  This lack of hypoxia may have protected 
against respiratory depression by increasing oxygen dependent metabolism of 
dichlorvos.  
 
There are potential differences in dichlorvos degradation between groups related 
to oxygen dependent metabolism but our understanding of how oxygen levels 
affect dichlorvos metabolism is incomplete. Dichlorvos is metabolized via two 
enzymatic pathways. The major pathway involves an “A”-type esterase and a 
minor pathway using glutathione-s-transferase[244]. Dichlorvos is rapidly 
degraded in tissue with a half-life of 19.9 minutes in rat whole blood[245] and 
none of the metabolites of dichlorvos inhibit acetylcholinesterase[246].  It is 
unknown if hypoxic conditions affect the rate of degradation of dichlorvos in the 
rat but this may have also contributed to the loss of autoresuscitative breathing in 
hypoxic animals. 
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Despite similar oxygen saturation, animals in Group II demonstrated significantly 
higher PaO2 post-apnea (table 5.2) when autoresuscitative breathing occurs.  It 
is possible that hyperoxia (Group II) during the autoresuscitative period 
stimulated autoresuscitative breathing over normoxia (Group I) but this seems 
less likely. Prolonged hyperoxia induces respiratory depression characterized by 
a larger drop in respiratory rate and a smaller increase in tidal volumes [247, 
248].  Indirect evidence against a hyperoxia requirement for autoresuscitative 
breathing is that hyperoxia has no known beneficial CNS effects over 
normoxia[249-251].  
 
Respiratory output during eupnea and gasping has been well described in the 
medical literature and OP-induced autoresuscitative breathing more closely 
resembles eupneic breathing.  The response of OP-induced autoresuscitative 
breathing was the reverse of what is described for gasping respiration.  
Autoresuscitative breathing occurred during a period of hyperoxia but gasping 
respiratory activity is supported by hypoxia[252].  Additionally, respiratory effort 
during autoresuscitative breathing, as measured by both esophageal pressure 
and phrenic activity, was less then half of baseline effort.  This is contrary to what 
occurs during gasping when respiratory effort is significantly increased.  Finally, 
the phrenic discharge waveform during autoresuscitative breathing does not 
match classical gasping, i.e. rising rapidly during inspiration with a definite pause 
in the expiratory position and uniform in depth[236].   
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Whether phrenic discharge activity during OP-induced autoresuscitative 
breathing represents a corruption of the CRO is debatable but OP-induced 
autoresuscitative breathing lacks the normal post-inspiratory, inspiratory activity 
(PIIA) of eupneic respiration.  PIIA represents inhibition of inspiratory neurons 
during early exhalation[253] and is characterized by a smaller decrescendo burst 
of activity during early exhalation.  It could be argued that the loss of the PIIA is 
related to decreased chemical drive from excessive mechanical ventilation (i.e. 
hyperoxic hypocapnia).  Hyperventilation decreases central respiratory 
activity[254, 255] and could theoretically decrease PIIA as well.  This is an 
unlikely explanation, as previous experiments have demonstrated increased PIIA 
during hyperoxic hypocapnia[256], the opposite of what was seen in this study.  
A possible mechanism for the loss of PIIA is afferent feedback to the CRO 
secondary to OP exposure to the brainstem or lung.  Mechanical stimulation of 
the airway with vagal feedback to the CRO results in a decrease in PIIA[256].  
We speculate that OP exposure to the lung may provide a similar feedback. 
 
In summary, apnea following acute OP poisoning is not absolute as respiratory 
activity resumes following a period of time post apnea.  Post-hypoxic respiratory 
depression occurs in animals hypoxic at the point of apnea even when 
oxygenation was maintained post apnea.  The resumption of respiratory activity 
represents an emergence of a respiratory oscillator distinct from eupnea and 
gasping and characterized by a loss of post-inspiratory inspiratory activity. 
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Our study design suffered from some limitations and did not allow us to 
independently control the oxygen saturation during the three time periods of the 
study (pre-apnea, at apnea, and post apnea). Further studies are needed to 
independently control oxygenation at those three time points and determine the 
effect (if any) on autoresuscitative breathing.  
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Table 5.1 – Characteristics of normoxic and hyperoxic study groups  
 
 Group I 
(n=10) 
Group II 
(n=6) 
 
Baseline    
     Respiratory Rate (bpm) 58.6 (7.9) 54.2 (4.7) P=ns 
     End Tidal CO2 (mmHg) 56.6 (5.2) 51.4 (1.1) P=0.053 
     Mean Arterial Pressure (mmHg) 88.8 (10.3) 106.8 (14.5) P=0.015 
     Oxygen Saturation (%) 97 (1.5) 98.5 (1.&) P=ns 
     Respiratory Effort (mmHg) - 3.54 (2.2) - 4.04 (2.5) P=ns 
FiO2 for entire experiment normoxic hyperoxic  
 
Mean (SD) values are for the last 5-minutes of the baseline period, prior to 
injection of dichlorvos.  Respiratory effort is the peak negative inspiratory 
pressure.  There was no statistical difference between groups for any of the 
baseline variables except for mean arterial pressure. 
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Table 5.2 – FiO2, time to apnea, and oxygen saturation (O2 sat) and partial 
pressure of oxygen in arterial blood (PaO2) for normoxic and hyperoxic study 
groups. 
 
 Group I Group II  
FiO2 Normoxic Hyperoxic  
Time to Apnea 3:38 (0:49) 5:39 (2:23) P=0.086 
Oxygen saturation (baseline) 96.8% (1.48) 98.5% (1.73) P=ns 
Oxygen saturation (apnea) 24.1% (39.1) 98.25% (2.36) P=0.001 
Oxygen saturation (post-
apnea) 
95.5% (3.37) 98% (2.83) P=ns 
PaO2 (baseline) 115.6 (7.0) 238.0 (14.1) P=0.0001 
PaO2 (post-apnea) 123.1 (22.3) 298 (22.6) P=0.0002 
 
 
Data are presented as mean (standard deviation).  Baseline data represents an 
average of data from 3 minutes preceding dichlorvos injection.  Apnea data 
represents a single point of data at the time point immediately prior to initiation of 
mechanical ventilation.  Post apnea period represents an average of 3 minutes of 
data starting 5 minutes after the point of apnea. PaO2 was obtained using arterial 
blood gas analysis for a selection of animals in each group (n=5 Group I, n=2 
Group II) and is presented in mmHg. 
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Figure 5.1 A,B – Physiologic tracings of single animals treated with dichlorvos 
poisoning and receiving mechanical ventilation initiated at the point of apnea. 
 
A. 
 
      
B. 
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Data represent a single animal poisoned with dichlorvos at time zero (fig 5.1a) 
with apnea occurring around 3.5 minutes and mechanical ventilation initiated 
around 4 minutes.  Note the negative deflections in the esophageal tracing (black 
bars) that represent respiratory effort despite mechanical ventilation.  A 
magnified view of the tracings is provided in fig 5.1b. 
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Figure 5.2A,B – Oxygen saturation and respiratory rate following injection of 
dichlorvos in normoxic and hyperoxic rats with mechanical ventilation at the point 
of apnea. 
 
Fig 5.2A 
 
Fig 5.2B 
 
Grouped data set shows oxygen saturation and respiratory rate for 
spontaneously breathing animals with acute OP and oxygen titrated to a PaO2 of 
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roughly 110 mmHg (5.2a) and 100% oxygen (5.2b).  Oxygen saturation reached 
a nadir at 10 min (24.1 +39.2%) in Fig 5.2a compared to a nadir of 98.0 (+3.7%) 
at 13 minutes in Fig 5.2b.  Respiratory rate is depicted with a dotted line and 
oxygen saturation is depicted with a solid line.  Animals were placed on 
mechanical ventilation at the point of apnea.  Dichlorvos was given at time zero. 
Results are shown as mean value +/- standard deviation.  
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Figure 5.3 – Correlation of respiratory rate and oxygen saturation.  
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Data are plotted as a scatter plot of individual animal respiratory rate and oxygen 
saturation during the first 4 minutes after injection of dichlorvos.  Data represent 
15-second bins of data.  Hyperoxic animals (crosses) demonstrate a range of 
respiratory rates at close to 100% oxygen saturation.  Normoxic animals (circles) 
demonstrate a general trend of lower respiratory rates with lower oxygen 
saturation and a number of outliers that do not follow that pattern.   
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Figure  5.4 – Autoresuscitative breathing in animals with hyperoxia and 
normoxia. 
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A comparison of autoresuscitative breathing between animals with 100% oxygen 
(Group II) and those with oxygen titrated to a PaO2 of around 110 mmHg (Group 
I).  Animals with titrated oxygen (group I) experienced hypoxia at the point of 
apnea and animals with 100% oxygen did not.  The percent of animals who 
demonstrated respiratory activity post-apnea is depicted as a bar and is 
referenced to the y axis on the right.  The number of actual breaths post apnea 
(in all animals) is depicted as a dot and is referenced to the y axis on the left.  
The p-value corresponds to comparing the percent of animals in each group with 
respiratory activity post apnea. 
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Figure 5.5 A,B,C – Phrenic Nerve activity pre and post apnea 
 
Fig 5.5A – Baseline phrenic activity 
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Fig 5.5B Autoresuscitative phrenic activity 
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Fig 5.5C – Event triggered average of phrenic activity pre and post apnea 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 A and B shows individual tracings of integrated phrenic nerve activity 
for baseline (A) and post apnea (B).  Activity is superimposed by synchronized at 
the initiation of phrenic activity.  Y-axis for A and B are arbitrary (related to 
amplification settings) but units are in volt- seconds.   Figure 5.5C shows an 
event triggered averaging of phrenic activity during the baseline period and post 
OP induced apnea (autoresuscitative breathing).  Data are an average of 100 
breaths for both the baseline period and post-apneic period.  Average peak 
integrated phrenic activity over 0.05 msec time blocks are plotted over time and 
 117 
synchronized to the onset of phrenic activity.  Activity occurring during the 
inspiratory period and post-inspiratory period of the respiratory cycle are labeled 
with black bars at the top of the graph.  The post-inspiratory activity was defined 
by the cessation of airflow (pneumotachometer).  Note the loss of post-inspiratory 
inspiratory activity during autoresuscitative breathing.  
 
 
 118 
Chapter VI - Location of action of Dichlorvos induced central apnea, effect of 
isolated exposure of the brainstem and pre-Botzinger complex. 
 
6.1 Abstract 
 
We demonstrated previously that OP poisoning causes a central apnea but the 
mechanism involved and location of action of the OP are not well understood.  
Respiratory control is located in the brainstem and involves a number of sites 
within the medulla and pons. The primary site of respiratory rhythm generation is 
in the medulla and is thought to be the pre-Botzinger complex which is a primary 
candidate for the CNS substrate both necessary and sufficient for OP-induced 
apnea due to it’s central role in respiratory rhythm generation and its known 
cholinergic inputs.  We performed a series of experiments exposing first the 
entire brainstem and then the pre-Botzinger complex alone to an OP.  Exposure 
of the brainstem to an OP resulted in a central apnea similar to apnea seen in the 
intact animal. However, exposure of the pre-Botzinger complex did not have a 
similar effect.  Exposure of bilateral pre-Botzinger complex to dichlorvos resulted 
in some respiratory depression but only 27% of the animals became apneic.  In 
summary, exposure of the brainstem to OP was sufficient to induce a central 
apnea but exposure of the pre-Botzinger complex alone was not sufficient. 
 
6.2 Introduction 
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Central apnea following acute OP exposure was described and characterized in 
chapter 2 but the location of action of the OP is unknown.  A number of 
brainstem sites have been implicated in OP-induced apnea. Exposure of the 
ventral surface of the medulla to cholinergic agonists results in a decrease in 
respiratory rate and tidal volume [48].  Injection of a small volume (10-60nl) of a 
cholinergic agonist into the medial portion of the rostral pons (near the pontine 
reticular formation involved in REM sleep) results in respiratory depression [49].  
Exposure of the pre-Botzinger complex in the medulla to elevated levels of 
acetylcholine modulates respiratory activity[50, 257].  
 
The pre-Botzinger complex in the medulla is considered by many to be the kernel 
of the central respiratory oscillator (CRO) responsible for generating inspiratory 
activity[88] and critical for eupneic respiration[237].  It is not clear if OP exposure 
to the pre-Botzinger complex is needed for OP-induced apnea as elevated 
acetylcholine levels in different areas of the brainstem result in respiratory 
depression[48, 50, 258] and elevated levels of acetylcholine in the pre-Botzinger 
complex increases respiratory activity[188]. The pre-Botzinger complex contains 
both muscarinic and nicotinic receptors that modulate respiratory activity[50, 187, 
188] but previous studies have used medullary slice preparations without the 
intact neural circuitry of a whole animal. In this section, we hypothesize that 
exposure of the pre-Botzinger complex to an OP is sufficient for OP-induced 
central apnea.  
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6.3 Methods 
 
Working Heart Brainstem Preparation 
The methodology used in the working heart brainstem has been previously 
published in detail[259].  Wistar rats (85-120 grams) were acquired and cared for 
in accordance with NIH published guidelines.  The institutional Animal Care and 
Use Committee of the University of Massachusetts approved this study protocol.  
Animals were housed in pairs and maintained on a 12-hour light dark cycle with 
food and water provided ad libitum. 
 
Rats were exposed to anesthetic gas (isoflurane, Sigma Aldrich, St Louis MO) in 
an anesthetic chamber until there was no withdrawal to foot pinch and respiratory 
activity was depressed.  The animals were removed from the anesthetic 
chamber, hemi-sected immediately below the diaphragm and the head, neck and 
thorax were immersed in iced artificial cerebrospinal fluid (125Mm NaCl, 5mM 
KCl, 1.25 mM MgSO4, 24 mM NaHCO3, 1.25 mM KH2PO4, 2.5 mM CaCl and 
10mM D-glucose).  The skull bone overlying the cerebral hemispheres and 
cerebellum was removed and the animal was decerebrated at the precollicular 
level, removing all brain tissue rostral to this transection with suction.  The 
diaphragm was dissected from its attachments to the ribs and spine and the 
anterior portion of the rib cage and sternum were removed, exposing the thoracic 
cavity.  The left phrenic nerve was identified and isolated from its surrounding 
connective tissue. The lungs were removed and the animal was transferred to a 
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recording chamber where the descending aorta was cannulated with a double 
lumen catheter.  The animal was then artificially perfused through the catheter 
with warmed artificial CSF plus 1.25% ficol (Sigma Aldrich, St Louis MO) 
equilibrated with a 5% CO2/95% O2 gas mixture.  The second lumen of the 
catheter was connected to a pressure transducer to monitor arterial pressure. 
 
Perfusion pressure was provided by a peristaltic pump (Watson Marlow, 
Falmouth, Cornwall) circulating artificial perfusate in a circuit from a reservoir, 
through the animal back to the reservoir.  The perfusate was warmed by passing 
through a heated water jacket (Neslab Instruments, Portsmouth NH) and filtered 
by passing through a bubble trap and filter paper (Millipore, Billerica MA).  
Perfusate seeped out of the open surgical sites of the animal before being 
collected in the basin of the recording chamber and pumped back to the reservoir 
of artificial CSF.  The reservoir was continuously bubbled with a 5%CO2/95%O2 
gas mixture.  A diagram of this technique is in figure 6.1. 
 
Sustained phrenic nerve activity was obtained after achieving appropriate 
perfusion pressure and temperature.  Increasing pump speed gradually over time 
increased perfusion pressure from 0 mmHg to a target perfusion pressure 
between 40 to 60 mmHg.  Once perfusion pressure reached the target range, 
temperature was increased by elevating the temperature in the water jacket to a 
target temperature of 29oC at the aortic catheter.  This temperature has been 
previously validated as the optimum temperature to support sustained respiratory 
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activity.  The phrenic nerve was draped over a bipolar electrode and encased in 
petroleum jelly. 
Artificial perfusion pressure was held in a constant range by increasing or 
decreasing pump speed during the experiment.   Data were recorded on a data 
acquisition system (Powerlab, ADI instruments) and displayed in real-time during 
the experiment (Chart, ADI instruments). Fictive respiratory rate and tidal volume 
(calculated from phrenic nerve activity) were monitored and recorded for changes 
in respiratory output. 
 
Microdialysis into pre-Botzinger complex 
Seven adult male Wistar rats were induced with 2.2% isoflurane (Abbott Labs, 
North Chicago, IL) and subsequently titrated to maintain an adequate respiratory 
rate (40-60 bpm) with sufficient anesthesia (monitored via foot pinch).  Animals 
underwent a tracheostomy but were allowed to breath 100% oxygen 
spontaneously at all times.  During a baseline period the animals were 
anesthetized with a constant amount of isoflurane (range 1.6-1.8%) that was not 
changed once the experiment began.  Physiologic recordings included 
respiratory (airflow, respiratory rate, end tidal CO2, oxygen saturation) and 
cardiovascular (blood pressure, pulse rate) parameters.  All animals served as 
their own control with comparisons made between baseline and post dichlorvos.  
Data were recorded using an A-D converter and PC data acquisition system (ADI 
instruments, Colorado Springs CO). 
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Animals were placed prone in a stereotactic apparatus with ear bars and bite 
block (Kopf Instruments, Tugunga California) and the skin overlying the skull was 
incised and retracted from midline. Bilateral 2mm trephination holes were drilled 
in the skull over the location of the pre-Botzinger complex using stereotactic 
coordinates (-3.3 intra-aural, 2 mm lateral).   A microdialysis guide cannula (CMA 
Microdialysis, North Chelmsford MA) was introduced into the holes to a depth of 
6mm.  A 2 mm long, 100 kDa cut-off microdialysis probe was inserted into the 
guide cannula.  If needed, the animal was allowed to return to baseline prior to 
proceeding.  The animal was maintained at a baseline level for at least 20 
minutes prior to initiating the experimental procedure.  All experimental protocols 
were approved by our institutional animal care utilization committee. 
 
Organophosphate Exposure and Controls 
 
Working heart brainstem preparation 
Respiratory rate and perfusion pressure were allowed to equilibrate for 10 
minutes prior to initiating the experiment.  Each animal served as its own control 
with 1 cc of vehicle (35% isopropyl alcohol) introduced into the artificial perfusate 
reservoir. Ten minutes following the vehicle control, dichlorvos (50 mg in 1cc of 
35% isopropyl alcohol) was introduced into the artificial perfusate reservoir.  
 
Microdialysis 
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In the microdialysis experiments the dichlorvos and control solutions were 
microdialyzed directly into bilateral pre-Botzinger complex.  Dialysis catheters 
placed in bilateral guide cannula were attached to a syringe pump filled with a 
dialysis solution.  The dialysis solution contained 12.5 mg/cc of dichlorvos mixed 
from a stock solution of 25 mg of dichlorvos solubolized in 1 cc of 35% isopropyl 
alcohol and 1cc of CNS perfusion fluid (CMA Microdialysis, North Chelmsford, 
MA).  Each animal served as its own control and vehicle alone (1:1 mixture of 
35% isopropyl alcohol and CNS perfusion fluid) was dialyzed for 12 minutes at 5 
!l per minute.  Animals were allowed to return to baseline for 10 minutes prior to 
exposure to dichlorvos. The dichlorvos solution was dialyzed at 5 !l per minute 
for a total of 12 minutes for a cumulative dose of 750 !g.   
 
Confirmation of probe placement was accomplished using KMnO4 to mark the 
center of the microdialysis probe membrane.  Following the termination of the 
experiment, the dialysis probes were removed from the guide cannula.  The 
bilateral guide cannula remained attached to stereotactic arms, and were not 
moved during the removal of the microdialysis catheter.  Needles extending just 
beyond the tip of the guide cannula were connected via tubing to a syringe pump 
(CMA Microdialysis, North Chelmsford, MA) and inserted into the guide cannula.  
KMnO4 (40mg/cc) was micro-injected at 8.3 !l/min for 5 min resulting in a direct 
oxidation of cells at the tip of the needle and a precipitation of manganese 
dioxide visible to the naked eye.  Animals were immediately perfused with 4% 
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paraformaldehyde and the brain was removed for sectioning and identification of 
probe tip location. 
 
Measurement of dichlorvos tissue level 
To assure adequate exposure of the pre-Botzinger complex following 
microdialysis, brain samples were sent for a determination of tissue dichlorvos 
levels.  An additional animal underwent dialysis of dichlorvos into the pre-
Botzinger complex as described above but was decapitated immediately after 
dialysis.  The brainstem was removed and frozen at -20oC, sectioned into 2mm 
slices, cut into 1mm by 1mm square sections, weighed and refrozen at -20oC. All 
samples of the brainstem, as well samples of a similar size from the forebrain, 
were sent for a determination of dichlorvos level using gas chromatography mass 
spectrometry (GCMS).  Barbra Evans at the UMMS Proteomic & Mass 
Spectrometry Core Facility analyzed samples.  As a control, samples of forebrain 
tissue from a naive animal (no intervention), and additional samples of forebrain 
tissue from a naive animal with dichlorvos added to the tissue sample post 
harvesting were also sent for a determination of dichlorvos level. 
 
Tissue samples were stored at -80 oC prior to extraction. Dichlorvos was 
extracted from the brain samples with ethyl acetate containing d6-dichlorvos 
internal standard and the extract directly analyzed by selected ion monitoring 
electron impact GCMS using a modification of the method described by Ma et 
al[260]. Brain samples were extracted by maceration and 5 min sonication in a 
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bath sonicator in 100 !l of ethyl acetate containing 7.5 ng of d6- dichlorvos 
internal standard. The extract was cleared by centrifugation for 5 min and the 
clear supernatant transferred to autosampler vials for GCMS analysis.  One !l of 
each sample was injected (splitless mode) onto a 30 mm X 0.25 mm ID DB5-MS 
capillary column that was connected directly to the ion source of a Waters 
Quattro-II triple quadrupole mass spectrometer.  Helium was used as the carrier 
gas at a constant flow of 1 ml/min and the column temperature was programmed 
from 75o C to 130o C at 30o C/min and held at 130o for 3.7 min. Electron impact 
ionization (EI) was used at 70 eV with the source at 225o C. Selected ion 
monitoring of m/z 108.9 (dwell 0.3 sec) for dichlorvos and m/z 114.9 (dwell 0.03 
sec) for the internal standard. External calibration standards containing 0.25, 0.5 
and 1.0 !g/ml of dichlorvos and 0.5 !g/ml internal standard were also analyzed 
before and after each 10 samples. The calculation of dichlorvos in each tissue 
sample was calculated from the ratio of the dichlorvos peak area to that of the 
internal standard multiplied times 7.5 ng. 
 
Data Analysis 
Data were obtained using a data acquisition system (ADI Instruments, Colorado 
Springs, CO) and recorded using Chart software. The primary endpoint was time 
to apnea.  Secondary endpoints included changes of respiratory and 
cardiovascular parameters from baseline.  Apnea was defined as a cessation of 
airflow through the pneumotachometer (or cessation of phrenic activity) for more 
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than 20 seconds.  Previous studies in our lab indicate that this definition reliably 
predicts an extended loss of respiratory effort. 
 
Raw phrenic signals were amplified (Cyberamp 320, Molecular Devices, 
Sunnyvale CA) and filtered (Humbug Noise Eliminator, Vancouver BC) prior to 
display.  Phrenic nerve activity greater then 3 standard deviations from baseline 
were rectified and step-wise integrated (time constant 50 ms).  Fictive tidal 
volume was calculated as a percentage of baseline, with 100% defined as the 
peak phrenic activity and 0% as zero.   Data are presented as mean (+/- SD) 
unless otherwise noted.  Comparison between groups is performed using 
student’s T-test where appropriate.  
 
6.4 Results 
 
Working brainstem spinal cord preparation 
Respiratory activity started after reaching an average perfusion pressure of 
44.6mm Hg and stabilized at a respiratory rate of 17.8 bpm during the baseline 
period prior to initiating the experiment.  There was no statistical change in fictive 
respiratory rate or fictive tidal volume with the exposure to vehicle alone. 
Respiratory activity began falling around 2 minutes after dichlorvos was 
introduced into the reservoir (figure 6.2).  Nine of 10 animals demonstrated a 
steady decline in respiratory rate and eventual apnea an average of 3 minutes 43 
seconds (+/- 2:47) post dichlorvos exposure.  Respiratory rate and fictive tidal 
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volume decreased in all animals over 50% and 75% respectively within two 
minutes of poisoning. 
 
Respiratory activity resumed post apnea in 8 of the 9 animals that demonstrated 
apnea. Respiratory activity resumed an average of 11 minutes 2 seconds (+/- 
11:57) after the point of apnea with some animals demonstrating a sustained 
respiratory activity (n=5) and others with a short burst of respiratory activity 
followed by a resumption of apnea (n=3).  Animals that demonstrated sustained 
post-apneic respiratory activity had phrenic bursts at a regular rate of 12.78 (+/-
4.28) breaths per minute.  The resumption of respiratory activity started regular 
but slow and increased gradually over time until the termination of the experiment 
1 hour post dichlorvos exposure.  
 
Perfusion pressure increased post dichlorvos exposure despite no change in 
pump speed.  Perfusion pressure increased 34% over baseline in all animals (10 
of 10), peaking 1.72 min (+0.28 min) post exposure.  This reaction was so 
reliable that it is now used as an indicator of dichlorvos exposure in this model. 
 
Microdialysis into pre-Botzinger complex 
Microdialysis of dichlorvos into the pre-Botzinger complex resulted in a 
progressive decrease in respiratory rate, volume of expired gas and minute 
ventilation but no change in mean arterial pressure or pulse rate (Figures 6.3 and 
6.4).  Apnea was seen in 28.6 percent of the animals (2 of 7) an average of 9.87 
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min after the initiation of dialysis.  Average respiratory rate, volume of expired 
gas and minute ventilation each declined 60% by the end of the study.  
Microdialysis of vehicle alone (35% isopropyl alcohol in artificial CNS fluid) had a 
minor effect on minute ventilation and tidal volume but did not cause apnea.  
Animals in this group showed no change in volume of expired gas but they did 
show an average 20% decrease in respiratory rate and minute ventilation.   
 
To determine the location of the microdialysis probes, KMnO4 was injected to 
mark the center of the 2mm microdialysis membrane.  KMnO4 injection 
successfully marked the location of the microdialysis catheter in 72% of animals.  
In some cases injection of the KMnO4 failed due to obstruction within the guide 
cannula.  Location of the microdialysis catheters is depicted in Figure 6.6.  A 
scatter plot of time to apnea vs distance from pre-Botzinger complex (figure 6.7) 
shows no correlation between the two data sets.  KMnO4 caused cellular 
coagulation and cell death resulting in apnea in 83% of the animals that were 
spontaneously breathing prior to the injection of KMnO4 (Figure 6.8).  In animals 
that were spontaneously breathing prior to the KMnO4, apnea occurred an 
average of 1:34 post initiation of injection with three of the animals becoming 
apneic within 6 seconds of initiating the KMnO4 injection.   
 
Dichlorvos levels in the brainstem are depicted in figure 6.9.  The areas of the 
brainstem closest to the dialysis catheter showed elevated levels of dichlorvos 
(1-2 µg/gm).  The two negative control samples from naïve animals showed 
 130 
levels of dichlorvos of 0.00 and 0.02 !g/g.  The small amount of dichlorvos in one 
of the negative controls was most likely due to cross contamination from the 
cutting surface during tissue harvesting. 
 
6.5 Discussion 
 
The working-brainstem preparation consists of the brainstem and spinal cord and 
retains the connections within the brainstem but lacks any afferent input from the 
cerebral hemispheres (decerebration) or feedback from the lungs (bilateral 
pneumonectomy).  Exposure of the brainstem to dichlorvos resulted in a 
cessation of respiratory activity on a time scale similar to our previously 
published whole animals model[186].  Exposure of the pre-Botzinger complex 
alone did not have the same effect.  Dichlorvos exposure to the pre-Botzinger 
complex resulted in respiratory depression but only 28.6% demonstrated apnea.  
Exposure of the pre-Botzinger complex to dichlorvos is insufficient for OP-
induced apnea. 
 
Dichlorvos exposure of the brainstem was sufficient for OP-induced central 
respiratory apnea.  Central respiratory control involves a network of 
interconnected neurons in the medulla and pons, and it is logical that exposure of 
this area is required for OP-induced central apnea.  At the heart of the central 
respiratory drive is the central respiratory oscillator responsible for the generation 
of rhythmic neural impulses resulting in inspiration. The pre-Botzinger complex is 
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considered by many to be the kernel of the CRO, has a central role in generating 
respiratory activity[261] and contains cholinergic receptors[50] that may be 
stimulated during acute OP intoxication.   
 
The lack of apnea following exposure of bilateral pre-Botzinger complex indicates 
that exposure of the pre-Botzinger complex alone is insufficient for OP-induced 
apnea.  Previous studies with OP exposure to the pre-Botzinger complex have 
shown similar results with respiratory depression but not apnea[50].  The 
brainstem contains many sites involved in respiratory control and a number of 
these sites are potentially involved in OP-induced central apnea but further 
research is needed.   
 
It is unlikely that insufficient dichlorvos exposure to the pre-Botzinger complex 
was responsible for the lack of effect.  Although placement of the microdialysis 
catheter showed slight variability, histological confirmation of the catheter tip 
showed that most catheter tips were within 2.0mm of the pre-Botzinger complex 
and there was no association between distance from the pre-Botzinger complex 
and respiratory depression.  The response to KMnO4 injection provides indirect 
evidence for accurate catheter placement in the area of central respiratory 
control and matches previously published studies on lesioning the pre-Botzinger 
complex[261].  Cell ablation at the tip of the catheter with KMnO4 caused apnea 
within 1.57 min, with 3 of the animals demonstrating apnea within 3 seconds of 
the initiation of the microinjection.     Most importantly, measured levels of 
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dichlorvos at the pre-Botzinger complex were sufficient to induce apnea. 
Dichlorvos levels at the pre-Botzinger complex were greater then previously 
published levels following lethal IV exposure.  Lethal IV dichlorvos (10mg/kg) 
generates a tissue level in the brain of 0.2-0.3 !g/g[245] and levels at the pre-
Botzinger complex in this study were greater then 1 µg/g.   
 
The kinetics of dichlorvos degradation may have played a minor role in the lack 
of respiratory effects following microdialysis.  The bio-effects of a single bolus of 
dichlorvos decrease over time as dichlorvos is rapidly degraded by two 
enzymatic pathways in the rat with the predominant pathway involving hydrolysis 
by an A-esterase present in the rat plasma and liver[262].  Introducing the 
dichlorvos over a protracted period during microdialysis of time should effectively 
decrease the peak exposure levels due to the increased time available for 
degradation. The half-life of dichlorvos in rat plasma is less then 15 min but this 
may be decreased with microdialysis.  Regardless of the kinetics of degradation, 
levels of dichlorvos at the pre-Botzinger complex were substantial as measured 
post-dialysis.  
 
In summary, dichlorvos exposure of the rat brainstem is sufficient for OP-induced 
central apnea.  Although the pre-Botzinger complex may be involved in OP-
induced apnea, dichlorvos exposure to the pre-Botzinger complex alone is 
insufficient.  
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Future Directions 
There are alternative sites in the brainstem that could be involved in OP-induced 
central apnea, but the few studies exploring these areas show mixed results.  
Cholinergic neurons are involved in the modulation of respiratory activity during 
sleep[263] and cause respiratory depression when stimulated[49].  Acetylcholine 
applied iontophoretically to individual respiratory related neurons in the ventral 
respiratory group produce changes in membrane potentials but have no effect on 
fictive respiratory rate or tidal volume[193, 195].  Cholinergic stimulation of the 
ventral medullary surface involved in chemosensitivity augments respiration[194]. 
Other cholinergic sites in the brainstem involved in respiratory control have not 
been rigorously studied. 
 
Limitations 
The working brainstem-spinal cord preparation produces a respiratory rate that is 
much lower then the native respiratory rate, implying changes at the neural level 
that may limit the generalizability of the findings in this model to the intact animal.  
In addition, the working brainstem-spinal cord model involves hypothermia and 
artificial perfusion that may introduce changes in the brainstem respiratory center 
unrelated to the dichlorvos exposure. 
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Figure 6.1 - Diagram of Working Brainstem-Spinal Cord Preparation 
 
 
 
Artificial perfusate is pumped from a reservoir through a warming jacket, bubble 
trap and filter. The decerebrate, hemi-sected animal lies in an open basin and is 
perfused through its aorta. Perfusate leaks out of the surgical sites and pools in 
the basin before returning to the reservoir that is continuously bubbled with a 5% 
CO2/95% O2 gas mixture.   
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Figure 6.2 A,B – Fictive respiratory activity post dichlorvos in the working 
brainstem spinal cord preparation 
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Fictive respiratory rate and tidal volume were calculated from an analysis of 
phrenic nerve activity.  Dichlorvos was introduced into the reservoir at time zero.  
Values are presented at a percentage of baseline activity with 100% equal to 
peak phrenic discharge (tidal volume) or rate of phrenic discharge (respiratory 
rate) during baseline period.   
 137 
Figure 6.3 A,B,C – Respiratory rate, volume of expired gas and minute ventilation 
post dialysis of dichlorvos into the pre-Botzinger complex 
 
A. 
 
B. 
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C. 
 
Microdialysis of dichlorvos into the pre-Botzinger complex was initiated at time 
zero.  Data represent an average of all animals. 
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Figure 6.4 A,B – Pulse rate and mean arterial pressure post dialysis of dichlorvos 
into the pre-Botzinger complex 
 
A. 
 
B. 
 
Microdialysis of dichlorvos into the pre-Botzinger complex was initiated at time 
zero.  Data represent an average of all animals. 
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Figure 6.5 – Microdialysis probe locations 
 
 
Dialysis probe location were marked using microinjection of KMnO4 at the 
midpoint of the 2mm x 0.4mm dialysis membrane. The grey squares represent 
the pre-Botzinger complex.  Black rectangles represent the 2mm dialysis 
membrane.  The red circle represents an injection site 2mm cephalad to the pre-
Botzinger complex.  Animals with inadequate KMnO4 injection resulting in an 
insufficient lesion on the histological specimen were not included. 
2 mm 
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Figure 6.6 – Relationship of changes in minute ventilation and average distance 
from pre-Botzinger complex. 
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The distance of the probe location from the pre-Botzinger complex was 
measured in three dimensions and plotted against time to 50% of baseline 
minute ventilation.  Each dot represents an average of both sites for a single 
animal.  Animals with inadequate KMnO4 injection resulting in an insufficient 
lesion on the histological specimen were not included. 
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Figure 6.7 A,B,C – Respiratory rate, volume of expired gas and minute ventilation 
post injection of KMnO4 into the pre-Botzinger complex 
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Microinjection of KMnO4 into the pre-Botzinger complex was initiated at time 
zero.  Data represents an average for control (2 of 2) and experimental (3 of 4) 
animals that were breathing at the end of the experiment.  Animals that were not 
breathing at the beginning of the KMnO4 injection were not included in this data 
set. 
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Figure 6.8 - Level of dichlorvos in brainstem following microdialysis of dichlorvos 
into bilateral pre-Botzinger complex. 
 
 
Microdialysis of dichlorvos (750 µg over 12 minutes) into bilateral pre-Botzinger 
complex was performed prior to sectioning the brainstem along dotted lines. The 
dichlorvos in each sample (1mm x 1mm x 2mm) was extracted and measured via 
gas chromatography-mass spectrometer.  The results are presented as µg of 
dichlorvos per gram of brain tissue.  A level greater then 3!g/g corresponds to a 
lethal level.  The pre-Botzinger complex location is depicted by a black circle. 
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Chapter VII – Summary 
 
 
7.1 Study findings 
 
Respiratory failure following acute dichlorvos poisoning involves an initial central 
apnea that occurs rapidly and is followed by a pulmonary dysfunction.  The 
central apnea occurs within minutes of poisoning and is characterized by 
decreasing respiratory effort, tidal volume and rate.  Vagal afferent feedback to 
the brainstem has a minor contribution to the central apnea but is not the driving 
mechanism of central respiratory failure.  Cerebral feed-forward input to the 
brainstem respiratory centers is not necessary for OP-induced central apnea.  
Exposure of the brainstem is sufficient for OP-induced central apnea but 
exposure of the pre-Botzinger complex alone (the central respiratory oscillator) is 
not sufficient for apnea.   
 
Respiratory failure following acute OP exposure is not permanent.  Animals 
supported with mechanical ventilation demonstrate a gradual re-emergence of 
respiratory activity following a period of apnea.  This re-emergence is 
characterized by an alteration of the phrenic output of the central respiratory 
oscillator that is distinct from normal eupneic respiration and gasping.  
 
Pulmonary dysfunction following acute OP exposure is not uniform.  Roughly 
20% of animals demonstrate a catastrophic increase in pulmonary secretions 
that fill the lung and trachea.  These animals die quickly despite mechanical 
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intervention.  The rest of the poisoned animals demonstrate a variability of 
dysfunction that is relatively short lived.  Studies with anti-cholinergic therapy 
indicate that transient dysfunction of the pulmonary vasculature is a component 
of the pulmonary dysfunction.  
 
7.2 Impact on Clinical Therapy  
 
The central apnea following acute OP poisoning occurs rapidly but is a greater 
concern for first responders, paramedics, fire and rescue personnel, and 
battlefield medics then physicians in a hospital setting.  The rapidity and 
uniformly lethal nature of the OP-induced central apnea prevents most untreated 
patients with OP-induced apnea from surviving to reach definitive care.  In 
addition, mass casualty triage in situations with OP exposures may require rapid 
endotracheal intubation and transport for those patients showing signs of apnea. 
In a battlefield situation, rapidly treating apneic patients without pulmonary 
dysfunction and transporting them to an inpatient facility would greatly increase 
their chances of survival without requiring significant additional resources.   
 
Unrecognized central apnea could cause problems clinically if the apnea was 
prolonged following exposure.  There are almost 900 different OP agents with 
subtlety different characteristics in fat solubility, tissue clearance and time course 
of effects.  Prolonged clinical effects would impact ventilated patients as well.  
Using pulmonary secretions to guide atropine therapy is a common clinical 
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strategy, but in mechanically ventilated patients this could result in failure to 
transition the patient off of the ventilator due to under-treatment of the central 
apnea.  Individuals with relatively smaller pulmonary effects but prolonged central 
apnea would receive little to no atropine.  Dosing atropine to inspiratory effort 
could provide a better strategy for those patients with little pulmonary 
dysfunction. 
 
Atropine is an effective therapy for severe OP poisoning but the effect of atropine 
on pulmonary vasculature has not been previously considered.  OP-poisoned 
patients can receive tremendous amounts of atropine, commonly in response to 
pulmonary dysfunction.  A common strategy for mechanically vented OP patients 
is dosing atropine with the clinical goal of “drying pulmonary secretions” to 
prevent hypoxia.   Unrecognized disruption in pulmonary gas exchange from high 
doses of atropine could be attributed to OP-induced pulmonary dysfunction, 
triggering more atropine.  Discerning between the hypoxic effects of pulmonary 
secretions and atropine-induced ventilation-perfusion mismatch requires 
recognition of the effects of atropine on pulmonary vasculature.  
 
The emergence of a distinct respiratory pattern post OP-induced apnea raises 
questions about the central respiratory oscillator and how it reconfigures when 
disrupted.  Previous authors have described respiratory activity post OP-induced 
apnea that is unaffected by repeated exposure to the same agent despite 
increased acetylcholine levels[166].  This combined with our findings implies a 
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fundamental change in the central respiratory oscillator.   Relatively little attention 
has been paid to characterizing reconfigured respiratory oscillators.  With wild 
speculation, it is possible to imagine inducing temporary changes in central 
respiratory control to stimulate sustained respiratory activity during a period of 
profound hypoxia, such as during cardiac arrest.  A compound that could induce 
neural respiratory activity during cardiac arrest would eliminate the need for 
cardiopulmonary resuscitation as we know it.  It is less speculative to imagine 
pre-treating soldiers with a compound that renders them immune to the apneic 
effects of nerve agents. 
 
7.2 Conclusions 
 
OP respiratory failure involves a combination of central apnea and pulmonary 
dysfunction.  OP-induced central apnea is rapid but transient and relates to direct 
exposure of the OP to the brainstem but exposure of the pre-Botzinger complex 
alone is insufficient.  OP-induced pulmonary dysfunction is variable and involves 
prominent pulmonary secretions and pulmonary vascular changes resulting in 
profound hypoxia. 
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